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PURPOSE: The primary purpose of this study was to compare balance in women 
with Multiple Sclerosis (MS), and healthy controls.  The secondary purpose was to 
investigate the relationship between balance and Expanded Disability Status Scores 
(EDSS) in patients with MS.  METHODS:  Subjects included 67 women with MS 
(X= 43.9 ± 1.2 years) and 45 healthy controls (X = 40.4 ± 2.4 years).  The MS group 
was diagnosed with this form of neurological disorder by a single MS neurologist and 
had a score of ≤ 5 on the EDSS. Both groups included women between 18-64 years of 
age who underwent a series of six balance measures by the use of the Neurocom 
Balance Master.  The MS group also filled out the MSQOL-54, and the healthy 
controls the PAR-Q and a Health Status Questionnaire. RESULTS:  There was a 
significant difference for weight between the MS (X = 76.8 ± 2.8 kg) group and 
healthy controls (X = 64.3 ± 1.6 kg), with the MS group being significantly heavier 
(p<0.01), but no significant differences were found for age or height (p> 0.05). For 
the following balance measures (deg/sec), there was a significant difference between 
the two groups, with the MS group doing worse for unilateral stance eyes open, 
unilateral stance eyes closed, tandem walk end sway, and  MCTSIB measures 
standing on foam surface with closed eyes (p<0.01).  Step quick turn (deg), did not 
differ significantly between the MS group and the healthy control group after 
adjusting for age (p >0.05).  Evaluating the EDSS subcomponents, there was a 
significant difference for sensory function and duration of disease in the MS group 
(p<0.05). CONCLUSIONS: The results from this study indicate significantly more 
x
postural instability in the MS group when compared to healthy controls. Also, the 
group diagnosed with MS for 10.1-20yrs had more impaired sensory function as 
measured by the EDSS compared to the other MS groups (.1-10yrs and 20.1-33yrs) 
(p<0.05).  
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CHAPTER I INTRODUCTION 
Multiple Sclerosis (MS) is a chronic, inflammatory, demyelinating, 
autoimmune disease that affects the central nervous system (CNS) 44. MS is the most 
common chronic, disabling disease of the CNS in young adults 23 with the onset of 
the disease at the age between 15-50 years with the peak at 30 years of age 44. The 
CNS consists of the brain, spinal cord, and the optic nerves. Surrounding and 
protecting the nerve fibers of the CNS is a fatty tissue called myelin, which helps 
nerve fibers conduct electrical impulses.  In MS, myelin is lost in multiple areas, 
leaving scar tissue called sclerosis. These damaged areas are also known as plaques or 
lesions. Often times the nerve fiber itself is damaged or broken.  Myelin not only 
protects the nerve fibers, but also makes their job possible and when myelin or the 
nerve fiber is destroyed or damaged, the ability of the nerves to conduct electrical 
impulses to and from the brain is disrupted, which produces the various symptoms of 
MS 44. MS is thought to involve an autoimmune reaction in which the body’s own 
immune system, attacks the myelin 44.
Caucasians, western European or people of Northern Scandinavian 
background seems to be most frequently affected by MS, and it is rare in certain 
ethnic and racial groups like Eskimos, Native American Indians and Africans 23.
Geographic locations play an important role, which is demonstrated by a very uneven 
global disease distribution especially in northern latitudes 23, 44. Some of the reasons 
for this could be the lack of sunlight in the winter months during pregnancy and 
therefore a lack of vitamin D.   
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Types of MS and Clinical Courses 
People with MS can expect one of four clinical courses of the disease, each of 
which might be mild, moderate, or severe.  The most common form of MS at the time 
of initial diagnosis is called Relapsing-Remitting MS and approximately 85% of 
people with MS have this form 44. People with this type of MS experience clearly 
defined flare-ups (also called relapses, attacks, or exacerbations).  These are episodes 
of acute worsening of neurologic function. They are followed by partial or complete 
recovery periods between the relapses and are free of disease progression 44.
Primary Progressive MS is a relatively rare form of the disease, which 
involves approximately 10% of the MS population 44. The characteristics of this type 
of MS experience a slow but a nearly continuous worsening of their disease from the 
onset, with occasional plateaus and temporarily minor improvements 44. This type of 
MS tends to involve the spinal cord more often and affect both men and women 
equally 44.
Secondary-Progressive MS is another form of MS with 50% of people with 
relapsing-remitting MS developing this form of the disease within 10 years of their 
initial diagnosis and 80% within 25 years if they go without treatment 44. People with 
this type of MS experience an initial period of relapsing-remitting disease, followed 
by a steadily worsening disease course with or without occasional flare-ups, minor 
recoveries (remissions), or plateaus 44.
Another rare type of MS is Progressive Relapsing MS, which involves 
approximately 5% of the MS population 44. The characteristics in people with this 
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type of MS experience a steadily worsening of the disease from the onset but also 
have clear acute relapses (attacks or exacerbations), with or without recovery 44. In 
contrast to relapsing-remitting MS, the periods between relapses are characterized by 
continuing disease progression. 
 MS afflicts about 400,000 people in the US and somewhere between 2-3 
million people worldwide.  It is more prevalent in women with women having 2-3 
time greater risk than men.  MS is associated with a reduction in bone mass and 
vitamin D deficiency that could be caused by prolonged use of steroids, progressive 
immobilization, lack of vitamin D and possible skeletal muscle atrophy 21. One of the 
reasons that there are an increased risk of fractures for people with MS is the risk of 
premature osteoporosis due to impaired mobility, and corticosteroid and vitamin D 
deficiency 51. People with MS may have decreased physical activity due to fatigue or 
physical limitations and decreased vitamin D intake may be due to the limited sun 
exposure because of MS related heat intolerance 51.
Pathophysiology of MS 
The exact cause of MS is unknown, but most researchers believe that the 
damage to myelin results from an abnormal response by the body’s immune system. 
Normally, the immune system defends the body against foreign invaders such as 
viruses or bacteria. In autoimmune diseases, the body attacks its own tissue and MS is 
believed to be an autoimmune disorder that leads to the destruction of myelin, 
oligodendrocytes and axons 41, 53. Myelin is the main target of the attack, but damage 
of axons and even death of axons can occur in the early stage of the disease 44. The 
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underlying mechanism of the disease is a disruption of the blood-brain barrier and 
migration of peripherally activated T-lymphocytes as well as auto antibodies into the 
CNS, which causes an inflammatory cascade 44. Further, cytokines that are pro-
inflammatory, causing an inflammation, are released and up-regulate lymphocytes 
and antigen-presenting cells 44. There is a secondary antigen-antibody response that 
causes destruction of the myelin as well as the myelin-producing oligodendrocytes 44.
The axonal conduction velocity is slowed down due to demyelination 43, 53. Once the 
myelin is gone, the axons can no longer transmit action potentials efficiently 44.
Clinical Manifestations 
Some of the common symptoms of MS are severe fatigue; sensory 
disturbances in the form of numbness and paresthesia; motor deficits due to 
imbalance, weakness and spasticity; vertigo; bladder dysfunction; heat sensitivity; 
decreased visual function due to optic neuritis and diplopia; and mental depression 44, 
53.
MS and Postural Balance 
In order to maintain dynamic postural balance the body relies on intact visual, 
somatosensory and vestibular input 3, central integration in the brain, and motor 
response 45. Postural impairments and balance, even when sitting, greatly affect the 
ability to perform activities of daily living and may thereby reduce the overall quality 
of life 37. It is common for people with MS to have equilibrium disorders caused by 
involvement of the brainstem and cerebellar structures because they are both 
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functionally linked in the control of sensory inputs and motor output 2. Further, the 
brainstem and cerebellum are also linked to the audiovestibular system, which is 
involved in multisensory integration and coordination of motor responses 2. The 
impaired balance by people with MS can be caused by weakness in muscle strength 
and compromised motor control 8. Various diseases of the central nervous system 
may also affect postural stability 28. Cognitive dysfunction in patients with MS may 
be the underlying risk factor for the increased risk of falls due to altered information 
processing, attention, decision making, error correction and execution of motor 
function 16. Also, decreased response time due to cognitive deficits can increase the 
risk of poor balance that otherwise would not have been altered 49. The risk for 
fracture as a result from falling is greatly increased, as much as 2-3 times, in patients 
with MS compared to healthy controls 51. Further, falls are the leading cause of 
accidental death in the elderly population and a decline in postural control is greatly 
influenced by inactivity 45. Evidence suggests that most patients with MS develop 
some form of progressive neurologic deterioration and within 10 years of onset will 
require a single-prong straight cane in order to ambulate safely 23. Within 20 years 
approximately 15% will require the use of a wheelchair 23.
PURPOSE 
The primary purpose of this study was to compare balance in women with 
Multiple Sclerosis (MS) and healthy controls.  The secondary purpose was to 
investigate the relationship between balance and the EDSS score in patients with MS. 
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RESEARCH QUESTIONS 
1.  Will women with MS have poorer performance on the balance tests than healthy 
controls? 
2.  Will the EDSS score correlate with postural balance measures in the MS group? 
3. Will the length of time from the diagnosis of disease affect the balance test 
performance?                                       
HYPOTHESES 
1.  It is expected that women with MS will have impaired balance compared to 
healthy controls due to secondary factors such as spasticity and ataxia.    
2.  There will be a negative relationship between the EDSS score and balance 
measures because it is an indicator of ambulatory function. 
3. It is expected that balance will decrease as the length of time from diagnosis 
increases.
SIGNIFICANCE OF THE STUDY 
The significance of the study is to provide an effective way to enhance 
postural stability in women affected by Multiple Sclerosis.  People diagnosed with 
MS often have difficulties with postural balance, due to secondary factors such as 
spasticity, and overall muscle weakness.  Participation in this investigation will make 
a contribution to science because the information obtained will help us understand the 
relationship of  postural balance in a population with MS compared to a healthy 
population.  This can lead to interventional strategies to improve balance and 
ambulation in patients with MS.  
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ASSUMPTIONS 
1. All subjects were diagnosed with a relapsing remitting type of MS by their 
neurologist.  
2. All subjects were not participating in vigorous exercise programs such as a 
resistance-training program. 
3. All subjects provided maximal effort on balance testing. 
4. All subjects provided honest answers on the questionnaires. 
DELIMITATIONS 
1. The response to balance training can only be applied to women between the ages 
of 18-64 years diagnosed with MS. 
LIMITATIONS 
1. Any sudden form of relapse during the study was not controlled. 
2. Daily activities performed outside this program were not controlled. 
OPERATIONS DEFINITIONS 
Multiple Sclerosis - Multiple Sclerosis is a neurological disease of the central nervous 
system (CNS), which consists of the brain and spinal cord.   
Relapsing Remitting form of Multiple Sclerosis - Characterized by relapses or 
exacerbations in which new symptoms appear or old symptoms gets worse followed 
by a period of remission.  During this time the subject may fully or partial recover 
from that relapse.                                                                                                                                                                      
Balance- Is the sense of equilibrium to maintain physical balance and is assessed by 
the Neurocom Balance Master.    
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EDSS- The Kurtzke Expanded Disability Status Scale (EDSS) and is a method to 
quantify disability in people with MS. EDSS scores between 1.0 to 4.5 refer to people 
with MS who are fully ambulatory, and EDSS scores between 5.0 to 9.5 are defined 
by the impairment to ambulation.                                                                                
Neurocom Balance Master- The Neurocom Balance Master® provides us with an 
objective assessment and retraining of both sensory and voluntary motor control of 
balance with visual biofeedback.  
Spasticity- Abnormal muscle tone or stiffness which is a manifestation of pyramidal 
dysfunction. Caused by damage to the corticospinal tract. 
Healthy Controls- Healthy women between 18-64 years of age that could be active 
but not involved in any weight training or be competitive athletes.  
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CHAPTER II REVIEW OF LITERATURE 
MS is an inflammatory, demyelinating, autoimmune disease affecting the 
CNS, and is known to be the most common chronic, disabling disease of the CNS in 
young adults 23 with the onset of the disease at the age between 15-50 with the peak at 
30 years old 44.
MS and Fatigue 
Severe fatigue that is unrelated to physical activity is one of the most common 
disabling symptom in MS with as many as up to 65% of individuals reporting fatigue 
as a limitation 4, 7, 22, 36, 38 and as many as 40% describing it as a disabling symptom 
and 15-40% describing it as the most important symptom 7. Often described as a state 
of exhaustion distinct from physical weakness or depression, often assessed by self-
report scales or performance-based measures 34. In contrast, Bakshi et al. (2000) 
found that fatigue in MS patients is associated with depression.   In a study by Krupp 
et al. (1997), they compared MS patients with healthy controls during structured 
interviews and fatigue proved to be more frequent as well as more severe among 
patients with MS.  The wide variety of MS-related fatigue between patients has 
suggested it to be caused by many factors like environmental heat and humidity, 
which is known to increase the symptoms of fatigue dramatically whereas cooling, is 
known to alleviate it 7, 36, 53. Suggested theories for fatigue are that there may be 
excessive cytokine factors that target areas of the brain that is in control of regulation 
of behavior and arousal states 23. Heat is an increased risk for discomfort for people 
with multiple sclerosis (MS) and approximately 60%-80% of all people with MS are 
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heat sensitive.  In a study by Freal et al. 22 they reported that 90% of the 656 MS 
patients reported that fatigue was worse at warmer temperatures and 83% reported 
worse fatigue following vigorous exercise and 64% after “moderate exercise”.  
Fifteen percent reported a reduction in fatigue with physical exercise.  Bergamaschi et 
al. (1997) examined 100 MS patients to assess frequency of fatigue and its 
relationship to other clinical findings and found that fatigue intensity and frequency 
were related to each other.  Further, fatigue was significantly worse with increased 
heat and chronic progressive disease.  Cooling by assistive devices or simply trying to 
stay in a cool environment has seemed to help alleviate the discomfort 19. Further, the 
use of a cooling-suit showed an increased ability for self-care during and after they 
had used it, as well as improvement and more ease to do daily life activities like 
walking as well as social activities because they could more easily participate in them 
19. Amantadine, which is a mild CNS stimulant, showed an improvement in fatigue 
in 62.5% of the subjects 38. The most commonly used medications for MS fatigue are 
amantadine and modafinil, which have proven positive results in controlled clinical 
trials 34.
It is very important to recognize and treat fatigue because it has a significant 
impact on the quality of life in patients with MS and can interfere with a person’s 




Another type of fatigue that there is limited information about is cognitive 
fatigue.  Cognitive dysfunction is very common in MS patients, affecting 50-65 % of 
all people suffering from MS 16, 48. This is in fact the most common reason why 
people with MS lose their employment 23. Further, there are reports stating that 
fatigue adversely affects their cognitive functioning 35. The areas most commonly 
affected are information processing speed and short-term memory function 23. In a 
study by Rao et al. (1991) they found that MS patients were much more likely to have 
more frequent impairments on measures of recent memory, sustained attention, verbal 
fluency and conceptual reasoning compared to healthy controls.  However, this 
cognitive dysfunction was not significantly correlated to duration of illness, 
depression, course of disease or medication usage, but correlated with physical 
disability.  In contrast, Feinstein et al. (1992) found that people with chronic 
progressive course of the disease, showed significant deterioration when it came to 
auditory attention tasks.   
MS and Bone Density 
Very few foods contain vitamin D with the exception of oily fish and the 
major source of vitamin D (90-95%) is from exposure to sunlight 26. There seems to 
be some association between vitamin D deficiency, living at higher latitudes and an 
increased risk of developing various autoimmune diseases like multiple sclerosis 26.
Children being born and living below 35° north latitude for the first 10 years of their 
lives had a 50% decreased risk of developing MS compared to children born above 
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35° north latitude 26. One may assume that MS is partially determined by where the 
individuals are living the first 10-15 years of their lives 23. Women with MS are at an 
increased risk compared to men for osteoporosis because of gender, immobility and 
corticosteriod use 39.
Prolonged periods of immobilization predispose bones to fractures due to the 
association with loss of bone and skeletal muscle 21. A study by Nieves et al. (1994) 
found that bone mineral density (BMD) of the lumbar spine and femoral neck, 
measured by dual x-ray absorptiometry were significantly reduced in MS patients, 
which may increase the risks for fracture two to three times.  Because that 80% of 
patients were below the recommended level of vitamin D and 40% reported no 
exposure to sunlight due to heat-intolerance it is safe to assume that the low BMD 
scores were due to vitamin D deficiency.  Corticosteroids are often used as a 
therapeutic measure by MS patients and one side-effect of long-term steroid use are 
commonly reduced bone density, through decreased mineralization and/or an 
increased rate of bone resportption 50. Prolonged use of corticosteriod is associated 
with catabolism of skeletal muscle and bone loss, which both predisposes bones to 
fractures, so therefore a patients with both prolonged immobilization and steroid use 
may have an increased risk of bone fragility and a reduction in skeletal muscle mass 
and that way have an increased risk of fractures 21. On the contrary, some researchers 
suggest that the use of corticosteroid does not impact bone mineral density.  Schwid 
et al. (1996) found no evidence that sporadic steroid pulses had any adverse affect on 
bone density of ambulatory MS patients.  Instead, bone densities increased following 
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their treatments.  There is a direct relationship between osteoporosis and inactivity so 
therefore; osteoporosis is a co-morbidity of MS.  Due to the decreased physical 
activity because of limited motor function and fatigue in MS, it can lead to 
sarcopenia, which contributes to osteopenia 53. The decrease of bone density caused 
by inactivity can lead to increased risk of falls and fractures 21. There is an enormous 
coverage of osteoporosis in women without disabilities; there is hardly any for 
disabled women 51. Shabas et al. (2000) surveyed 220 women with MS and found 
that 50% of the women did not take calcium supplements and 71% did not take 
Vitamin D supplements. Further, a 40% reduction of the incidence of getting MS was 
seen in people with increased vitamin D intake 26. It is imperative for people with 
MS to take extra supplements of calcium and vitamin D to prevent further reduction 
in bone density and to avoid falls leading to fractures, caused by a combination of 
decreased bone density and neurological impairments.  
MS and Spasticity 
Spasticity is affecting more than 90 percent of MS patients leading to 
abnormal gait leading to unsteadiness, abnormal motor performance, postural 
instability and loss of dexterity.  Baclofen is known as an antispastic drug to control 
spasticity in MS patients since 1967 42. In a study done by Ørsnes et al. (2000) they 
found an increased postural steadiness in MS patients in all direction while walking.  
With baclofen treatment, right leg unsteadiness was reduced significantly.  Although 
baclofen is highly effective it can cause significant muscle weakness, so the preferred 
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drug is tizanidine because it does not cause muscle weakness in addition to reducing 
muscle spasm 23.
MS and Pain 
Pain is one of the most common symptoms in patients with MS.  It is a very 
frequent and disabling problem that can impair motor function and ambulation.  
Reports have shown a great variation of pain prevalence from 28.8% to 82% and it is 
very difficult to study because all people experience different symptoms 5. This 
disabling can have an effect on daily activities, which was reported by 40% in the 
survey by Beikse et al. (2004).  Pain can be limiting in itself and in this survey pain 
was most frequently located in the limbs and lumbar region, which can cause 
difficulties walking, standing or even keeping your balance.  It can be either from 
musculoskeletal changes directly related to MS or secondary to damage to central 
sensory fibers (neuropathic pain).   
MS and Postural Balance 
In order to maintain dynamic postural balance the body relies on intact visual, 
somatosensory and vestibular input 3, central integration in the brain and motor 
response 45. Postural impairments and balance, even when sitting, greatly affects the 
ability to perform activities of daily living and may thereby reduce the overall quality 
of life 37. It is common for people with MS to have equilibrium disorders caused by 
involvement of the brainstem and cerebellar structures because they are both 
functionally linked in the control of sensory inputs and motor output 2. Further, the 
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brainstem and cerebellar are also linked to the audiovestibular system, which is 
involved in multisensory integration and coordination of motor responses 2. The 
impaired balance by people with MS can be caused by weakness in muscle strength 
and compromised motor control 8. Various diseases of the central nervous system 
may also affect postural stability 28. Cognitive dysfunction in patients with MS may 
be the underlying risk factor for the increased risk of falls due to altered information 
processing, attention, decision making, error correction and execution of motor 
function 16. Also, decreased response time due to cognitive deficits can increase the 
risk of poor balance that otherwise would not have been altered 49. The risk for 
fracture as a result from falling is greatly increased, as much as 2-3 times, in patients 
with MS compared to healthy controls 51. Further, falls are the leading cause of 
accidental death in the elderly population and a decline in postural control is greatly 
influenced by inactivity 45. Evidence suggests that most patients with MS develop 
some form of progressive neurologic deterioration and within 10 years of onset will 
require a single-prong straight cane in order to ambulate safely 23. Within 20 years 
approximately 15% will require the use of a wheelchair 23.
Ways to improve balance in people with MS is imperative in order to prevent 
any further injuries from falls and increased independence and quality of life.  There 
are many different ways that have been researched and have shown to be beneficial 
for postural balance, like medicine, supportive devices to natural medicine.  Ankle 
foot orthoses are known to improve static balance in patients with MS.  Tai chi is 
another way to improve balance, which is a Chinese Martial Art system emphasizing 
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on a person’s strength, balance, flexibility and speed with limited jumps and kicks 1.
It is a slow-moving martial art that originated in China thousands of years ago, and 
appears to benefit people with chronic disabling conditions 32. The basic postures and 
exercise technique in Tai Chi is stretching, stances, palm pushes and punches 1.
During an 8-week intervention program with Tai Chi there was a 21% increase in 
walking speed and a 28% increase in hamstring flexibility for 19 MS patients 32.
Some researchers have suggested that smoking marijuana have beneficial effects in 
spasticity in people with MS 22. In a study by Greenberg et al. (2005) they 
hypnotized that smoking marijuana would result in better postural control and 
produce great therapeutic benefit due to the relieve in spasticity.  However, the results 
revealed that smoking marijuana as a form of treatment resulted instead in an 
interference with sensory-motor signals that lead to unstable postures.  Others have 
found that marijuana decreased tremors is some subjects. An overall increase in 
cardio-respiratory fitness, muscle strength and endurance, and reduced fatigue seem 
to increase the ability to perform tasks for daily living in people with MS.     
MS is a chronic, inflammatory, demyelinating, autoimmune disease that 
affects the CNS and is the most common chronic, disabling disease of the CNS in 
young adults. There are many factors that are suggested to cause MS, from genetics, 
gender to environmental factors as the underlying cause.  MS is really a disabling 
disease usually affecting women in their early 30’s, when they are planning a family 
and this disease is obviously causing great concerns.  Many common symptoms of 
MS is characterized by severe fatigue, cognitive fatigue, sensory disturbances in the 
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form of numbness and/or paresthesia, motor deficits caused by gait imbalance, 
weakness and spasticity, vertigo, bladder dysfunction, sexual dysfunction, heat 
sensitivity, unilateral decreased visual function due to optic neuritis and diplopia as 
well as mental depression. Because an increase in cardio-respiratory fitness, muscle 
strength, muscle endurance and reduced fatigue seem to increase the ability to 
perform tasks for daily living in people with MS, it is highly recommended as a form 
of treatment beside pharmacological treatments.  Planning and support from friends, 
family and spouses is also important, so that the ones with the disease can have an 
increased quality of living.    
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CHAPTER III METHODOLOGY 
The primary purpose of this study was to compare balance in women with MS 
and healthy controls.  The secondary purpose was to investigate the relationship 
between balance and the EDSS score in patients with MS. 
Subjects 
Subjects for this study were women between 18 and 64 years of age diagnosed 
with relapsing remitting type of MS. All subjects in this study were volunteers 
selected from the MS Center of Mercy Hospital in Oklahoma City in agreement with 
the medical director.                                                                                                          
Inclusion Criteria for Subjects with MS 
1) Subjects were diagnosed with MS by a physician; 2) Subjects had a score 5 or 
below on the expanded disability status scale; 3) Subjects were fully ambulatory 
without assistive device; 4) Subjects had a mental capacity to give written 
informed consent and comply with the proposed protocols; 5) Subjects consisted 
of females between the ages of 18-64 years. 
Inclusion Criteria for Healthy Controls 
1) Subjects consisted of females between the ages of 18-64 years; 2) Subjects had a 




Exclusion Criteria for Subjects with MS 
1) Women not in the age-group 18-64 years; 2) Males; 3) Women with a higher 
score than 5 on the expanded disability status scale; 4) Women who were not fully 
ambulatory; and 5) Women who were pregnant. 
Exclusion Criteria for Healthy Controls 
1) Women not in the age-group 18-64 years; 2) Women who were pregnant; 3)
Anyone with physical disabilities preventing them from being tested (ie. 
orthopedic or arthritic problems) were not allowed to participate in the study; 4) 
Anyone who participated in vigorous exercise, including resistance-training 
programs; 5) Males. 
Research Design 
Prior to any testing the subjects obtained medical clearance from their MS-
physician and signed an informed consent approved by the Institutional Review 
Board at the University of Oklahoma and Mercy Hospital.  The subjects were tested 
during a single testing session, which took approximately 30 minutes.  
Subjects with MS: 
a. Were required to read and sign an informed consent form before testing. 
b. Filled out a Multiple Sclerosis Quality of Life-54 instrument (MSQOL-54), which 
is a structured, self-report questionnaire concentrating on physical and mental 
health.   
c. Obtained medical clearance from their MS physician.               
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d. A series of six balance measures were done in one testing session by using the 
Neurocom Balance Master, which is a computerized postural sway assessment 
device.  This devise is designed to measure postural balance and sway on a firm 
surface as well as on a foam surface, with eyes open and closed.  Instructions 
were given on the computer screen before the actual testing.  Three trials were 
performed for each test and qualified personnel conducted the tests. 
Healthy Controls: 
a. Were required to read and sign an informed consent form before the testing. 
b. Filled out a Health Status Questionnaire and a PAR-Q.  
c. A series of six balance measures were done in one testing session by using the 
Neurocom Balance Master, which is a computerized postural sway assessment 
device.  This devise is designed to measure postural balance and sway on a firm 
surface as well as on a foam surface, with eyes open and closed.  Instructions 
were given on the computer screen before the actual testing.  Three trials were 
performed for each test and qualified personnel conducted the tests. 
Balance Measures 
The measures of balance were done using the Neurocom Balance Master (NeuroCom 
International, Inc).  This is a computerized postural sway assessment device, which is 
designed to measure postural balance and postural sway by a series of impairment 
and functional tests.  Instructions were given on the computer screen about foot 
placement prior to actual testing.  All analysis of tests was given numerically using 
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percentages, ratios, as well as a comprehensive version using pictures and graphs of 
pattern of movements.  Postural stability was conducted for both groups as well as the 
controls.  
Modified Clinical Test for Sensory Integration of Balance (MCTSIB) 
Description 
This assessment examined postural sway velocity while the subject was 
standing still on the force platform with eyes open and then closed.  Greater sway 
indicated less stability and less sway indicated greater stability.  This assessment was 
able to identify abnormalities in the sensory system contributions to postural control.  
Each trial lasted 10 seconds.   
Conditions 
There were three trials for each of the four conditions: EO (Eyes Open) Firm 
Surface; EC (Eyes Closed) Firm Surface; EO Foam Surface and EC Foam Surface. 
Instructions 
The subject was instructed to keep their eyes open or closed and look straight 
ahead while standing upright as steady as they possible could.  The computer showed 
foot placement and indicated when trial session were over.   
Variables 
There were a total of four variables used in this analysis and were as 
following; Sway Velocity Firm and Foam Composite score, Mean COG Sway 
Velocity, and COG Alignment.  By adding the two scores for eyes open and closed 
and dividing by two for each condition we created the two variables to get Composite 
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Sway Velocity.  Sway Velocity is a ratio of distance traveled by the center of gravity 
to the time of the trial (10 seconds).  Sway Velocity for each of the conditions gave us 
Mean Center of Gravity Sway Velocity.  In all conditions, a low score indicated less 
sway, indicating that the subjects were more stable during assessment and a high 
score indicated more sway, indicating that the subjects were unstable during 
assessment.  The Center of Gravity Alignment is a direct reflection of subject’s center 
of gravity over their base of support.  In order to project good balance individuals 
need to hold their center of gravity near the center of the base.  
Unilateral Stance (US)   
Description 
This analysis measured postural stability by quantifying postural sway while 
the subject was standing on one foot only on the force plate with eyes open and eyes 
closed.  The greater the sway the greater the instability, and the less the sway the 
greater the postural stability.  The length of the test was 10 seconds. 
Conditions 
There were three trials in each of the four conditions: EO Left Foot; EO Right 
Foot; EC Left Foot; EO Left Foot. 
Instructions 
Subjects were asked to keep their eyes open or closed while shifting weight 
from one foot to the other following instructions.  They were instructed to stand as 
steadily as possible for 10 seconds on each leg.  The computer screen illustrated the 
foot placement prior to testing and indicated when the test is over. 
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Variables 
For this analysis, two variables were used, Sway Velocity Eyes Open and 
Eyes Closed.  Sway Velocity for each variable was defined as the ratio of distance 
traveled by the Center of Gravity to the time of the trial (10 seconds).  Mean Center 
of Gravity Sway Velocity was the average of the center of gravity scores from both 
right and left leg stance with eyes open or closed.  A low score indicated less sway 
and more stability during testing.  
Limits-Of-Stability (LOS) 
Description 
This analysis examined the subject’s ability to voluntarily sway to various 
locations in space and the ability to maintain that position briefly.  The parameters 
examined were reaction-time, sway velocity, directional control, endpoint excursion 
and maximum excursion.  Each trial lasted 8 seconds. 
Conditions 
There were eight trials in the following order: Forward; Forward-Right; Right; 
Backward-Right; Backward; Backward-Left; Left and Forward-Left. 
Instructions 
The subject’s Center Of Gravity was displayed on-screen as a cursor, 
providing visual feedback.  The subject controlled the cursor by shifting her weight.  
The goal was for the subject to lean accurately and quickly in order for the cursor to 




Sway Velocity with Eyes Open in order to follow the cursor on the computer 
screen was the variable for this analysis.  
Tandem Walk (TW) 
Description 
This assessment examined the subject’s gait along a platform heel to toe.  The 
parameters measures were: step width, speed and end of sway velocity. 
Conditions 
Three trials were done with the subject walking heel to toes along the length 
of the platform. 
Instructions 
Standing position of the subject was heel to toe as steadily as possible.  At 
instructions, the subject walked as quickly as possible along the platform with heel to 
toe at each step.  Once reaching the end of platform they were asked to hold still for 
five seconds.  Prior to exercise, a movie was shown to explain the task. 
Variables  
The variables used in this assessment were Step Width, Speed and Sway with 
the mean taken for all three trials for each variable.  Step Width was the distance (cm) 
between the right foot and left foot on consecutive steps.  Average Speed was the 
same as the velocity (cm pr sec), and Sway (degrees/sec) was defined as the 
anterior/posterior movement during the five-second pause following the walk test. 
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Step Quick and Turn (SQT) 
Description 
This assessment measured postural balance by quantifying turn performance 
following two steps forward and pivoting 180 degrees.  The parameters measured 
were turn-time and turn-sway velocity. 
Conditions 
This test consisted of three trials with left foot first followed by the right foot, 
depending on the preference by the subject. 
Instructions 
The subject’s start position was in an upright position until they were signaled 
by the computer screen to “Go”.  Then the subject took two steps forward, pivoted 
around quickly to either left or right and returned by taking two steps back to starting 
position. Again, prior to exercise, a movie was shown to explain the task. 
Variables 
The two variables used in this analysis were mean turn sway and mean turn 
time, with the mean being the average of the three trials done.  Turn Sway (deg/sec) 
explained the postural control during the turn of each trial performed.  Turn Time was 
defined as the number of seconds that the subject used in order to perform a full 180-
degree turn.  Once the subject began leaning forward and movement was detected in 
opposite direction, scoring began. 
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Step up/Over (SUO) 
 Description                                                                                                                   
This assessment measured several movement characteristics such as the 
subject stepping up onto a curb with one foot, lifting the other foot over the curb and 
placed it down on the floor, and then stepped down with the curb foot.  The 
parameters measured were rising index, movement time and impact index.  
 
Conditions 
This test consisted of three trials of both conditions, involving both left foot 
first and right foot first. 
Instructions  
The subject’s start position was in a standing upright position until they were 
signaled by the computer screen to “Go” in which they quickly stepped up onto the 
curb with the foot of their preference, lifting the other foot over the curb and stepped 
down with the other foot and were standing as steadily as possible until trial was over.  
Again, prior to exercise, a movie was shown to explain the task in detail. 
Variables 
The variables measured in this assessment were rising index (force to rise), 
movement time and impact index (impact force).  Rising index was defined as the 
average force exerted by the step-up leg.  This was expressed as a percentage of body 
weight.  Mean movement time was defined as the average time used to complete the 
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step over, measured in seconds.  Mean impact index was defined as the average 
maximum force that was transmitted through the lagging leg as it hit the surface, also 
expressed as a percentage of body weight. 
 
MSQOL-54 
The Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) is a 
structured, self-report questionnaire that the patient can complete with little or no 
assistance.  There are two summary scores with the MSQOL-54 – physical health and 
mental health.  Further there are 12 subscales and they include: physical function, role 
limitations-physical, role limitations-emotional, pain, emotional well-being, energy, 
health perceptions, social function, cognitive function, health distress, overall quality 
of life, and sexual function. There are also two single-item measures, which include 
satisfaction with sexual function and change in health.  The test takes approximately 
11-18 minutes to complete.   
 
Data Analyses 
All descriptive analyses were reported as means ± standard error for both the 
MS group and the healthy control group.  For outcome measures with multiple trials, 
a repeated measures ANOVA was used to see if the data could be averaged across the 
three trials.  Bonferroni post hoc analyzes was used in conjunction with the repeated 
measures analyses. To analyze descriptive data and balance measures between the 
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healthy controls and the MS group, an independent t-test was used. To express all 
data relative to length of disease, the X ± SE were grouped into three time periods, 1= 
.1-10yrs; 2= 10.1-20yrs; and 3= 20.1-33yrs.  To compare the three different lengths of 
the disease, a one-way ANOVA and Bonferroni as a post-hoc measure was used to 
compare the three groups (.1-10yrs; 10.1-20yrs; 20.1-33yrs) for each outcome 
measure.  ANCOVA was used to compare means of balance measures for the three 
groups based on duration of disease, using age as a covariate.  To evaluate any 
potential relationship between EDSS scores and balance scores, Pearson Correlation 
Coefficients were used for the entire MS group and then separated by duration of 
disease.  To evaluate any potential relationship between EDSS scores and MSQOL-
54 scores, Pearson Correlation Coefficients were used for the entire MS group and 
also separated by duration of disease. 
The significance level was set at p ≤ 0.05 and all statistical analysis was 
performed by SPSS 12.0.  
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CHAPTER IV RESULTS AND DISCUSSION 
The primary purpose of this study was to compare balance in women with MS 
and healthy controls.  The secondary purpose was to investigate the relationship 
between balance and EDSS in patients with MS.   
Physical Characteristics                                                                                                  
There was no significant difference (p> 0.05) in age between the MS group (X 
= 44.0 ± 1.2 yrs) and the healthy controls (X = 40.4 ± 2.4 yrs).    Further, there was no 
significant difference in height (cm) between the MS group (X = 163.5 ± .95) and the 
healthy controls (X = 164.1 ± .82); however, there was a significant difference in 
weight between the MS (X = 76.8 ± 2.8) group and healthy controls (X = 64.3 ± 1.6), 
with the MS group being significantly heavier (p = .000) (Table 1). 
 
Table 1. Physical Characteristics for healthy controls and MS population 
 
Parameter Group N X SE P-Value 
Age (yrs) Control   






























There were no significant trial effects for measures with multiple trials on the 
balance measures, so the average of all three trials were used for each measure, with 
the exception of Modified Clinical Test for Sensory Integration of Balance 
(MCTSIB) test with eyes closed.  There was a significant difference between trial 1 
and trial 3, so the average of trials 2 and 3 were averaged and used.   
For unilateral stance, right leg (deg/sec) with eyes open (USCOGEO), a 
significant difference was seen between the MS group (X = 4.1± .60) and the healthy 
group (X = .95 ± .03), (p = .000).  The MS group had more postural instability during 
this activity.  Small scores are good and indicate little postural instability whereas 
larger scores are worse and indicate more movement.   
Unilateral stance, right leg (deg/sec) with eyes closed (USCOGEC) also 
showed a significantly difference between the MS group (X = 10.9 ± .33) and the 
healthy group (X = 1.8 ± .08), (p = .000).  Again, this indicates significantly more 
movement in the MS group and thus less postural stability.                                                                                                                             
Tandem walk end sway (deg/sec) (TANDEM) was significantly different 
between the MS group (X = 5.1 ± .46) and the healthy group (X = 3.1 ± .15), (p = 
.000).  The healthy group demonstrated lower sway scores than the MS group, and 
low scores are good and indicate good postural balance while higher sway scores 
indicate less balance. 
For the MCTSIB measure (deg/sec), there was a significant difference 
between the MS group (X = 1.6 ± .18) and healthy controls (X = 1.2 ± .06), with the 
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MS group having higher scores and worse postural stability while standing on foam 
surface with eyes closed (p = .025). 
The step quick turn (deg) test (SQT) did not differ significantly between the 
MS group and the healthy control group (p = .951) (Figure 1 and Table 2).   
Subject numbers for the MS group varied throughout the balance testing due 
to fear of participating in some of the tests.  They thought they would not be able to 
do it or they were too scared to try.  
 















** Significant at the 0.01 level, * Significant at the 0.05 level 
**   
 *
** 
 **     
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Table 2. Balance Measures for Healthy Controls and MS population 
Balance 
measures 
























































** Significant at the 0.01 level, * Significant at the 0.05 level 
 
Outcome Measures Based on Duration of Disease                                                                               
In order to examine if the duration of the disease had any effect on the 
different outcome measures, the MS subjects were categorized as group1 (.1-10yrs 
since MS diagnosis); group 2 (10.1-20yrs since MS diagnosis); and group 3 (20.1-
33yrs since MS diagnosis).                                                                           
Physical characteristics based on duration of disease
The estimated mean age for the individuals with MS was 44 ±1.2 years, and 
the mean duration of disease for the group as a whole was 8.08 ± .96 years (Table 3). 
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Table 3. Duration of disease for MS group 
Duration of MS N X SE 
1 = .1-10 yrs 48 4.22 .40 
2 = 10.1-20 yrs 10 14.10 1.01 
3 = 20.1-33 yrs 7 26.00 1.41 
Total 65 8.08 .96 
When separating the MS population into 3 separate groups based on duration 
of disease, there was a significant difference in age (p = 0.029) between group 1 (X = 
42.1±1.5) and group 3 (X = 52.0±2.3), with group 3 being significantly older than 
group 1 (p = .043) (Figure 2).  No difference was found between groups based on the 
duration of disease for height or weight (Table 4). 
 





















Table 4. Physical Characteristics Based on Duration of Disease 
 
Parameter Group N X SE P-Value 







































*Significant at p<0.05 
Balance Measures                                                                                                                             
A significant difference was found between groups (p = .002) for unilateral 
stance with eyes open, right leg (deg/sec).  A Bonferroni post hoc was done and the 
difference was found between group 1 and 3 (p = .009).  This indicates that group 3 
(X = 8.3±2.3) had poorer scores on unilateral stance with eyes open compared to 
group 1 (X = 2.8±.55), (Figure 3).  















a,b denotes significant difference between the groups, 1 and 3 (p ≤0.01)





Further, there was a significant difference (p = .000) found between groups on 
MCTSIB mean on foam surface with eyes open.  Bonferroni post hoc analysis 
indicated that group 1 (X = .67±.03) and group 3 (X = 1.2±.15) were significantly 
different (p = .000), (Figure 4).  


















a,b denotes significant difference between the groups, 1 and 3 (p ≤0.01)
Foameo= Stance on foam eyes open. 
For MCTSIB on firm surface with eyes closed there was also a significant 
difference (p = .015) between group 1 (X = .48±.07) and group 2 (X = 1.2±.53).  In 
all the conditions, high sway scores are worse and low sway scores are good, 
suggesting better postural balance.  So, for these two tests, people that had been 
diagnosed longer with MS as is group 2 (10.1-20yrs) and group 3 (20.1-33yrs) scored 
worse than people in group 1 that had only been diagnosed with MS for .1-10 yrs. 




















a,b denotes significant difference between the groups, 1 and 2, and 1 and 3 (p ≤0.05) Firmec= 
Stance on firm eyes closed. 
For the step up and over (SUO) test for the right leg, there was a significant 
difference (p = .020) between the groups.  Bonferroni post hoc found the difference to 
be between group 1 (X = 1.8±.08) and group 3 (X = 4.80±2.7), (p = .018).  This was 
also the case for the left leg (p = .023), with group 1 (X = 1.7±.06) and group 3 (X = 
4.5±2.5), (p = .019).  Since the subject is asked to do this task as fast as possible, low 
scores indicate fast movement and are better than high scores that indicate slower 
movement.  For both of these tasks the group that had been diagnosed with MS for 
the longest duration was significantly slower than the group that had been diagnosed 
the shortest time (Figure 6).  The ANCOVA results, which utilized age as the 
covariate did not change the original ANOVA findings, based on duration of MS 
diagnosis for the balance measures of unilateral stance eyes open, standing on foam 
eyes open and standing on firm surface with eyes closed.  Only the step up and over 






respectively following the ANCOVA protocol.  This might indicate that the group 
with the longest MS diagnosis was slower than the other two groups due to increased 
age rather than duration of MS. 















Duration of disease did not affect tandem walk end sway (p = .373), MCTSIB 
foam eyes closed (p = .136), unilateral stance mean with eyes closed (p = .487), 
unilateral stance left leg eyes closed (p = .439) or eyes open left leg (p = .156), step 
quick turn mean (p = .344), step quick turn, left leg (p = .517), or any of the eight 
measurements of limits of stability for the group affected by MS.     
MSQOL-54                                                                                                                    
There was no significant difference between any of the 12 subscales of the 
“The Multiple Sclerosis Quality of Life-54 Instrument” and duration of MS, 
indicating that for this group the length of the disease had no significant impact on 





any aspect of quality of life as measured with this instrument (Figure 7). The scores 
for the MSQOL-54 range from 0 (low QOL) and 100 (high QOL).  

















For all MS subjects combined, the overall quality of life had the highest score 
(X = 71.11 ± 2.1), and energy/fatigue had the lowest score (X = 40.36 ± 2.5).  This 
indicates that the individuals in this study perceived their overall quality of life quite 
high although they experienced fatigue (Table 5). 
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Table 5. Descriptive statistics for MSQOL-54 
 
MSQOL-54 DATA X SE 
Overall QOL 71.11 2.1 
Social Function 70.63 2.7 
Emotional Well-being 68.96 2.2 
Mental Health Comp 68.32 2.3 
Pain 65.27 3.0 
Health Distress 64.77 2.9 
Health Distress Mental 64.77 2.9 
Role Limitation Emotion 64.59 5.5 
Physical Function 62.13 3.6 
Cognitive Function 60.98 2.9 
Sexual Function 60.05 3.9 
Physical Health Comp 59.44 2.3 
Health Perception 54.88 2.2 
Role limitation Physical 52.39 5.1 
Energy/Fatigue 40.36 2.5 
EDSS                                                                                                                              
The expanded disability status scale was performed by their MS physician and 
the scale takes into account disability or dysfunction according to pyramidal, 
cerebellar, brain stem, sensory, bowel and bladder, visual, cerebral and other 
functions.  Each of these subcomponents was graded from 0-10 depending on the 
severity of the disability, with 0 being normal and indicating no disability and 10 
“death” by MS.  The only subcomponent of the EDSS that had a significant 
difference between the different durations of disease was sensory function (p = .031).  
Bonferroni post hoc analysis indicated that group 1 (X = .22±.06) and group 2 (X = 
.80±.38) were significantly different (p = .040) (Figure 8).  
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Table 6. EDSS scores based on duration of disease, X ± SE 
 
Parameter 0.1-10 yrs 10.1-20 yrs 20.1-33 yrs 
EDSS 1.4 ± .15 2.0 ± .35 2.07 ± .22  
Pyramidal .66 ± .12 .70 ± .21 1.0 ± .30 
Cerebellar .22 ± .08 .30 ± .21 .42 ± .29  
Brainstem .06 ± .03 .00 ± .00 .14 ± .14 
Sensory .22 ± .06 .80 ± .38 .57 ± .29 
Bowel/Bladder .31 ± .09 .50 ± .26 .85 ± .26 
Visual .41 ± .12 .10 ± .10 .28 ± .28 
Cerebral .52 ± .12 .60 ± .33 .71 ± .35 
Other .04 ± .04 .20 ± .20 .28 ± .28 
For the entire MS group, pyramidal (X = .69± .09) and cerebral (X =.59± .11) 
areas of the EDSS were the most affected (Figure 9).  At any stage of the disease, 
evidence of pyramidal involvement seems to be quite common. For cerebral (mental), 
bowel and bladder, pyramidal, cerebral, brainstem and “other” symptoms, the group 
with the disease the longest also experienced more dysfunction.  
 














.1-10 10.1-20 20.1-33 Combined







The final part of the statistical analyses involved computing Pearson 
Correlation Coefficients between measures of EDSS (disability) and quality of life 
with measures of balance.  
EDSS and Balance 
The expanded disability status scale was composed of eight separate 
components (pyramidal, cerebellar, brain stem, sensory, bowel and bladder, visual, 
cerebral and other functions) or the scale could be expressed as a single value 
(expanded EDSS).  The EDSS components range in values between 0 (no disability) 
to 10 (death by MS) with low scores indicating better function.  Similarly, low 
balance scores compared to higher values indicated better postural stability.  
Therefore it would be expected that the relationship between EDSS score and balance 
scores would be positive.   
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.39** .35** .29*  .29*  .26*     
Pyramidal         .32* .33*  
Cerebellar     .25* .32*      
Brainstem         .67** .69**  
Sensory   .27*    .45**    -
.27* 
Bowel/Bladder    .29*        
Other .40**   .34* .47*   .33** .98** .98**  
* p<0.05, ** p<0.01 
In general there were positive, low to moderate relationships between EDSS 
scores and balance measures with the expanded EDSS having the greatest number of 
significant relationships with balance.  
 
Table 8.  The effect of duration of disease on the relationships between EDSS and 






















.49**  .33*    .47** .37* -
.41** 
Pyramidal         .30* 
Cerebellar .32*  .38*  .36*    -.37* 
Brainstem   .32*      .32* 
Visual       .57** .51**  
Cerebral .37*     .29*    
* p<0.05, ** p<0.01 
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Sensory .80*  .66*    
Bowel/Bladder .96**      
Visual   .97**    
Other  .82**  .97** -
.92** 
-.79* 
* p<0.05, ** p<0.01 
 

























Pyramidal     .85*       
Cerebellar .99**           
Brainstem  .99** .99** .84*      .87*  
Sensory           .85* 





Visual      -
.80* 
 
Cerebral       .86* .83*    
Other  .99** .99** .84*      .87*  
* p<0.05, ** p<0.01 
 
In general, when examining balance measures within the MS group basing it 
on the duration of disease, the group that had been diagnosed the longest (20.1 – 33 
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years) did worse on the balance tests.  As the length of disease increased there were 
stronger positive correlations between EDSS and balance. 
EDSS and MSQOL-54 
The relationship between EDSS (and their 8 subscales) and The Multiple 
Sclerosis Quality of Life-54 Instrument (MSQOL-54) (including physical and mental 
health, and their 12 subscales) was also examined.  
Table 11. EDSS and MSQOL-54 
 
MSQOL-54 EDSS Pyramidal Cerebellar Sensory Bowel/Bladder Cerebral 
Social 
Function 






-.33**     -.37** 
Pain      -.34** 
Health Distress -.25*      
Health Distress 
Mental 
-.25*      
Role Limitation 
Emotional 
-.36**    -.32** -.32* 
Physical 
Function 
-.61** -.32* -.44**   -.27* 
Cognitive 
Function 
 -.31* -.29* 
Physical 
Health Comp 
-.45**  -.31*  -.32** -.44** 
Health 
Perception 
 .25*  -.33** 
Role limitation 
Physical 
-.33**  -.32**  -.31* -.34** 
* p<0.05, ** p<0.01 
 
When examining EDSS scores and MSQOL-54, negative correlations were 
expected since low scores on EDSS would indicate low disability and would then 
correspond to a higher score for quality of life.  In general there were negative, low to 
45
moderate relationships between EDSS scores and MSQOL-54 with the cerebral 
component having the greatest number of significant relationships with MSQOL-54.  
 
MSQOL-54 and EDSS based on duration of disease 
 
Table 12. Duration of MS, Group 1 (.1-10yrs) 
MSQOL-54 EDSS Pyramidal Cerebellar Brainstem Bowel/Bladder Cerebral 
Social 
Function 






-.37**     -.43** 
Pain      -.38** 
Health Distress -.34*   -.31*   
Health Distress 
Mental 
-.34*   -.31*   
Role Limitation 
Emotional 
-.40**    -.33* -.40** 
Physical 
Function 
-.65** -.44** -.48**  -.31**  
Cognitive 
Function 
 -.34* -.38** 
Physical 
Health Comp 
-.54**  -.35*  -.46** -.50** 
Health 
Perception 
-.34*    -.41** -.54** 
Role limitation 
Physical 
-.40**  -.29*  -.40** -.37** 
Overall QOL   -.29*   -.33* 
* p<0.05, ** p<0.01 
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Table 13. Duration of MS, Group 2 (10.1-20yrs) 
 







 -.66*   .69* 
Mental Health 
Comp 
 -.65*  
Role Limitation 
Emotional 
 -.76*  
Cognitive 
Function 
 -.80**  
Energy/Fatigue -.82**     
* p<0.05, ** p<0.01 
 
Table 14. Duration of MS, Group 3 (20.1-33yrs) 
 








Energy/Fatigue .82*  
Overall QOL  .80* 
* p<0.05, ** p<0.01 
 
Overall, the mental health composite of the MSQOL-54 increased over 
duration of disease, indicating that the individuals that had had MS the longest also 
had better mental health.  This could be explained by that these individuals have 
come to term with their disease and are doing well.  For physical health composite, 
individuals that had had the disease from 10.1-20 years indicated the worse physical 
health. The “newly” diagnosed group and the group that had had the disease the 
longest had better scores on physical health.  For overall EDDS scores, individuals 
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that had the disease for 10.1-20 and 20.1-33 years had the same higher score than the 
group with the disease for 0.1-10 years, indicating that the groups having the disease 
the longest also was more symptomatic. 
DISCUSSION  
There can be several reasons for balance disturbances in individuals with MS.  
The most common source for poor balance in MS is demyelination in the cerebellar 
connections in the brainstem, particularly lesions located in the vestibular nuclei 
(dorsal midbrain) (Burks and Johnson, 2000). Depending on the location, a 
demyelinating lesion can cause either trunk or limb ataxia.  In MS, limb ataxia is 
more commonly seen and is caused by lesions in the cerebellar peduncles, which is 
the connection between the cerebellum and the brain stem (pons) (Burks and Johnson, 
2000).  Other secondary factors that affect balance are loss of proprioception (sensory 
ataxia), muscle weakness and spasticity.  Loss of proprioception is important because 
that function provides the needed information about limb location without actually 
having to look at them.  Areas of demyelination can cause delayed conduction, still 
allowing the brain to receive input but in a delayed fashion. In MS, in addition to 
demyelination there can be loss of function due to loss of conduction capability in 
some axons from transected axons or neuron cell death (Burks and Johnson, 2000).  
Muscle weakness is a loss of muscle strength that can be caused by damage in the 
corticospinal tract, which can affect balance and the ability to walk.  If there is 
damage in the corticospinal tract, the level of disability depends both on the level and 
the location of the lesion (Burks and Johnson, 2000).  Spasticity is generally caused 
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by lesions in the part of the brain or spinal cord that controls voluntary movement 
(Burks and Johnson, 2000).  Spinal spasticity is very common in individuals with MS 
and is caused by lesions located in the spinal portion of the corticospinal tract.   
The MS group and the healthy control group did not differ in age or height, 
but the MS group was heavier than the healthy control group.  This could possibly be 
explained by a more sedentary lifestyle due to MS related dysfunctions.  Fatigue is 
commonly reported in people with MS and can be of either central or peripheral 
origin 11. Research has suggested that the site of a lesion, particularly if in the 
pyramidal tracts, increases fatigue 33. Severe fatigue in MS patients, which has been 
estimated to be as much as 125% more than in healthy subjects, could contribute to a 
sedentary lifestyle in this population 11, and thus more weight gain.  
For the balance measures there were also differences found between the two 
groups.  The MS group demonstrated significantly greater sway and movement 
during all balance activities with the exception of step quick turn test, compared to 
healthy controls.  This was expected, as individuals with MS often have trouble with 
postural stability secondary to lesions in the cerebellum or the pathways connecting to 
it.   
When examining balance measures within the MS group, basing it on the 
duration of disease, the group that had the disease the longest did worse on the 
balance tests, demonstrating more sway.  A cross sectional study 18 interviewed each 
participant with MS twice and found that 26 of the 27 people reported loss of balance 
as the most common symptom of their MS and approximately half the group said it 
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interfered a lot with their daily activities.  Multiple studies have reported an increased 
incidence of fall with increase in age 15. But, there are also several other symptoms as 
a result of MS that can influence postural stability, such as fatigue, weakness, 
numbness, spasticity, tremors, decreased coordination and pain 17.
Quality of life has been widely studied with the MS population using the 
MSQOL-54, which is a questionnaire standardized for MS populations.  Living with a 
chronic immune-mediated disease of the central nervous system that has no cure can 
often lead to decreased quality of life, and depression is frequently seen.  This 
questionnaire takes into account several aspects of life such as physical and mental 
functioning as well as social, sexual, and emotional well-being.  It has been widely 
accepted as a critical and valuable measure for well-being in the MS population 6, 24, 
29. For this investigation there were negative correlations between EDSS scores and 
MSQOL-54 scores, indicating that as individuals report higher quality of life scores, 
they also had lower disability scores.  This is in agreement with a study by 46, were 
they reported patients with higher EDSS having reduced quality of life scores 
(HRQoL).   
Although there were no significant relationships between duration of disease 
and quality of life in our study similar to Fruehwald et al. (2001), others have found 
that disease duration had a significant effect on mental dimensions of quality of life 46 
and that it differ across disease course but varied by duration of disease as well as age 
20. They actually also reported a higher quality of life in people with longer duration 
of disease and suggested that older people may be more likely to perceive themselves 
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as having a good quality of life, whereas young people may have a negative outlook 
on quality of life because of the uncertainties they may be facing in the future as a 
consequence of MS.   
Kurtzke’s expanded disability status scale (EDSS) is a functional assessment 
heavily based on mobility and does not cover very well other areas of disability and 
health, such as pain, vitality or emotional problems 29, 40. It further has been criticized 
for poor reliability 25 but is an acceptable tool for individuals with increased disability 
31. The EDSS measured by a physician takes into account disability or dysfunction 
according to pyramidal, cerebellar, brain stem, sensory, bowel and bladder, visual, 
cerebral and other functions.  Each of these components are graded from 0-10 
depending on the severity of the disability, with 0 being normal and indicating no 
disability and 10 death by MS.  The results of this investigation did not show any 
difference among these sub components other than sensory, with group 2 (diagnosed 
with MS for 10.1-20) yrs having more disability than group 1 (diagnosed with MS for 
.1-10 years).  Otherwise, there was an increase in disability on all sub components 
with exception for visual and sensory, with group 1 having the lowest scores and 
group 3, (diagnosed with MS for 20.1-33yrs) the highest scores, thus indicating more 
disability as duration of disease increased.  
Disturbances in balance and gait are frequently observed in individuals with 
MS 14 and have been defined as the most common symptom in some individuals 18, 54,
and seen in as much as 18-63% in MS patients 27. There are many factors that play a 
role in this, but most commonly it is caused by demyelination of the cerebellum and 
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the connecting pathways.  Postural imbalance can be caused by a single isolated 
lesion in a single pathway or be caused by multiple lesions involving several motor 
and sensory systems 10. Further, demyelination of the vestibular pathways can also 
cause dizziness, loss of balance and ataxia 30. In this investigation, the individuals 
demonstrated a positive correlation on most of the sub-components of the EDSS and 
the balance measures, indicating that with increased dysfunction in the various areas 
of the brain there was also a trend towards more postural imbalance.  There was a 
higher score of dysfunction for the pyramidal function than for any other area within 
this group.  However, there was a very low score of dysfunction located in the 
cerebellar area, which is most commonly affected in patients with poor balance.  
When examining this based on duration of disease, the oldest group (Group 3) which 
had the disease the longest also had the highest EDSS, indicating more total 
dysfunction.  Group 3 and group 1 had the highest dysfunction in the pyramidal area 
of the brain, whereas group 2 had mostly sensory dysfunction.                                                                  
Multiple Sclerosis is one of the most common degenerative diseases of the 
central nervous system in young adults and is characterized by focal demyelination 
and axonal loss within the central nervous system 54. Destruction of the myelin that is 
produced by the oligodendrocytes causes an interruption of saltotary conduction 
along the myelin sheath 54, which translate into clinical symptoms.  Sometime there 
can be death of the nerve or the axon itself, and other times if the axon is preserved 
re-myelination can occur 54. This re-myelination of axons in the CNS is initiated by 
Schwann cells and oligodendrocytes and can enhance the impaired conduction 12.
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This is responsible for improvement of symptoms in the relapsing form of the disease, 
allowing for clinical “silent” or symptom free periods with clinical improvement.    
This cross-sectional study investigated overall postural balance in women 
with MS and compared them to healthy controls.  Because this disease is both chronic 
and progressive in nature, it is hard to predict what the future holds for this population 
in regard to their physical abilities, especially without the use of medication.  It is 
imperative to start with medications as soon as diagnosis is set to prevent future 
damage, since there is no cure for this disease. General impairments of mobility can 
be detrimental to people of any age, but especially in older adults and even more for 
people with disabilities that interfere with daily activities.  Previous research have 
reported balance disturbances in as much as 23-84% of people with MS 52, with 
delayed and distorted proprioception being the main reason for postural imbalance in 
individuals with MS 10. Many of these impairments can be secondary to motor 
weakness or numbness, which is seen in up to 80% of people with MS 18, 47, or
prevalence of profound fatigue in people with MS 11. When postural stability is 
compromised by any of the above factors it can have a detrimental effect on people’s 
everyday lives and overall quality of life.  With an ongoing and progressive 
worsening of the disease, the ability of maintaining balance to do daily tasks such as 
walking without any assistive devices and everyday chores, the individual has to 
prepare not only physiologically but also psychologically.  It could possible affect 
their ability to maintain their independence and suddenly they may have to face the 
reality of depending on others.  The results of this investigation demonstrated that 
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individuals with MS do have increased postural instability compared to the healthy 
population.  Further, it also showed that people diagnosed with MS for a longer 
period of time also demonstrated poorer postural balance than people that had not 
been diagnosed for as long.  Therefore, studies like this and future studies are 
encouraged to gain information that can help with interventions to increase balance in 
individuals with neurological disorders.  
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CHAPTER V CONCLUSIONS 
The primary purpose of this study was to compare balance in women with MS 
and healthy controls.  The secondary purpose was to investigate the relationship 
between balance and the EDSS score in women with MS aged 18-64 years.  The 
research conclusions drawn from this study were: 
1.  Will women with MS have poorer performance on the balance tests than 
healthy controls? 
Yes.  The MS group did significantly worse in four of the five balance measurements 
and those included unilateral stance with eyes open and eyes closed, tandem walk and 
standing on foam surface with eyes closed.  There was no difference between the two 
groups when performing step quick and turn.  
2.  Will the EDSS score correlate with postural balance measures in the MS 
group?  
Yes. In general there were positive, low to moderate positive relationship between 
EDSS scores and balance measures with the expanded EDSS having the greatest 
number of significant relationships with balance.  This was what we expected since 




3.  Will balance decrease as the length of the time from diagnosis increase?  
Yes. When examining postural balance in the MS group, basing it on the duration of 
disease, the group that had been diagnosed the longest did worse on the balance tests, 
demonstrating more postural instability.   
LIMITATIONS OF THE STUDY 
One of the limitations of this study was that it only included women with 
relapsing remitting form of MS, so they were fully ambulatory.  This could affect 
balance measures as a progressive form of MS is much more disabling. Also, 
medications were not controlled for in this study and anti spasticity medication like 
Baclofen is common for MS patients and could have influenced the results.  The 
testing was done at different times for every subject and some subjects may have been 
fatigued at the end of the day, which is very common for people with MS. 
SUGGESTIONS FOR FUTURE RESEARCH 
Postural balance has been recognized as one of the most common problems 
with MS.  With this study and other studies it has been established that MS patients 
are having more trouble with postural balance compared to the healthy population. 
More studies including both genders should be done to identify the most limiting 
component of balance and interventions including resistance training, stretching, yoga 
and weight training should be implemented in the work out program for these 
individuals so that the quality of life for the MS population could be dramatically 
increased.   
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PURPOSE: The primary purpose of this study was to compare balance in women 
with Multiple Sclerosis (MS), and healthy controls.  The secondary purpose was to 
investigate the relationship between balance and EDSS scores in patients with MS. 
METHODS:  Subjects included 66 women with MS (X= 43.9 ± 1.2 years) and 45 
healthy controls (X = 40.4 ± 2.4 years).  The MS group was diagnosed with this form 
of neurological disorder by a single MS neurologist and had a score of ≤ 5 on the 
EDSS. Both groups included women between 18-64 years of age who underwent a 
series of six balance measures by the use of the Neurocom Balance Master.  The MS 
group also filled out the MSQOL-54, and the healthy controls the PAR-Q and a 
Health Status Questionnaire. RESULTS:  There was a significant difference for 
weight between the MS (X = 76.8 ± 2.8 kg) group and healthy controls (X = 64.3 ± 
1.6 kg), with the MS group being significantly heavier (p<0.01), but no significant 
differences were found for age or height (p> 0.05). For the following balance 
measures (deg/sec), there was a significant difference between the two groups, with 
the MS group doing worse for unilateral stance eyes open, unilateral stance eyes 
closed, tandem walk end sway, and  MCTSIB measures standing on foam surface 
with closed eyes (p<0.01).  Step quick turn (deg), did not differ significantly between 
the MS group and the healthy control group after adjusting for age (p >0.05).  
Evaluating the EDSS subcomponents, there was a significant difference for sensory 
function and duration of disease in the MS group (p<0.05).CONCLUSIONS: The 
results from this study indicate significantly more postural instability in the MS group 
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and thus less postural stability when compared to healthy controls. Also, the group 
diagnosed with MS for 10.1-20yrs had more impaired sensory function as measured 
by the EDSS compared to the other groups  (p<0.05).  
INTRODUCTION 
Multiple Sclerosis (MS) is a chronic, inflammatory, demyelinating, 
autoimmune disease that affects the central nervous system (CNS) 44. MS is the most 
common chronic, disabling disease of the CNS in young adults 23 with the onset of 
the disease at the age between 15-50 years with the peak at 30 years of age 44. The 
CNS consists of the brain, spinal cord, and the optic nerves, and surrounding and 
protecting the nerve fibers of the CNS is a fatty tissue called myelin, which helps 
nerve fibers conduct electrical impulses.  In MS, myelin is lost in multiple areas, 
leaving scar tissue called sclerosis, also known as plaques or lesions. Often times the 
nerve fiber itself is damaged or broken.  Myelin not only protects the nerve fibers, but 
also makes their job possible and when myelin or the nerve fiber is destroyed or 
damaged, the ability of the nerves to conduct electrical impulses to and from the brain 
is disrupted, and this produces the various symptoms of MS 44.
MS and Postural Balance 
In order to maintain dynamic postural balance the body relies on intact visual, 
somatosensory and vestibular input 3, central integration in the brain, and motor 
response 45. Postural impairments and balance, even when sitting, greatly affects the 
ability to perform activities of daily living and may thereby reduce the overall quality 
of life 37. It is common for people with MS to have equilibrium disorders caused by 
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involvement of the brainstem and cerebellar structures because they are both 
functionally linked in the control of sensory inputs and motor output 2. Further, the 
brainstem and cerebellum are also linked to the audiovestibular system, which is 
involved in multisensory integration and coordination of motor responses 2. The 
impaired balance by people with MS can be caused by weakness in muscle strength 
and compromised motor control 8. Various diseases of the central nervous system 
may also affect postural stability 28. Cognitive dysfunction in patients with MS may 
be the underlying risk factor for the increased risk of falls due to altered information 
processing, attention, decision making, error correction and execution of motor 
function 16. Also, decreased response time due to cognitive deficits can increase the 
risk of poor balance that otherwise would not have been altered 49. The risk for 
fracture as a result from falling is greatly increased, as much as 2-3 times, in patients 
with MS compared to healthy controls 51. Further, falls are the leading cause of 
accidental death in the elderly population and a decline in postural control is greatly 
influenced by inactivity 45. Evidence suggests that most patients with MS develop 
some form of progressive neurologic deterioration and within 10 years of onset will 
require a single-prong straight cane in order to ambulate safely 23. Within 20 years 
approximately 15% will require the use of a wheelchair 23.
PURPOSE 
The primary purpose of this study was to compare balance in women with MS and 
healthy controls.  The secondary purpose was to investigate the relationship between 




Subjects for this study were women between 18 and 64 years of age diagnosed 
with relapsing remitting type of MS. All subjects in this study were volunteers 
selected from the MS center of Mercy Hospital in Oklahoma City in agreement with 
the medical director there.   
Inclusion Criteria for subjects with MS were that they must have been 
diagnosed with MS by a physician; scored 5 or below on the expanded disability 
status scale, and be fully ambulatory without assistive device.  Inclusion criteria for 
healthy controls were that they were women in the age group between 18-64 years old 
and that they did not participate in vigorous exercise program.  
Research Design 
Prior to any testing the subjects obtained a medical clearance from their MS-
physician and signed an informed consent approved by the Institutional Review 
Board at the University of Oklahoma and Mercy Hospital.  The subjects were tested 
during a single testing session, which took approximately 30 minutes.  
Subjects with MS filled out a Multiple Sclerosis Quality of Life-54 instrument 
(MSQOL-54), which is a structured, self-report questionnaire concentrating on 
physical and mental health.  Healthy controls read and filled out a Health Status 




The measure of balance was done using the Neurocom Balance Master 
(NeuroCom International, Inc), which is a computerized postural sway assessment 
device, designed to measure postural balance and postural sway by a series of 
impairment and functional tests.  The tests that were done were the following:   
Modified Clinical Test for Sensory Integration of Balance (MCTSIB), which is an 
assessment examining postural sway velocity.  Unilateral stance which measures 
postural stability by quantifying postural sway while the subject is standing on one 
foot only on the force plate with eyes open and eyes closed.  Limits of stability 
(LOS), which examines the subject’s ability to voluntarily sway to various locations 
in space and the ability to maintain that position briefly.  For theses tests, greater 
sway indicates less stability and less sway indicates greater stability. Tandem walk 
which examines the subject’s gait along a platform heel to toe.  Step Quick and Turn 
(SQT), which is an assessment that measures postural balance by quantifying turn 
performance following two steps forward and pivoting 180 degrees.  
Data Analyses 
All descriptive analyses were reported in means ± standard error for both the 
MS group and the healthy control group.  For outcome measures with multiple trials, 
a repeated measures ANOVA was used to see if the data could be averaged across the 
three trials.  Bonferroni post hoc analyzes was used in conjunction with the repeated 
measures analyses. To analyze descriptive data and balance measures between the 
healthy controls and the MS group, an independent t-test was used. To express all 
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data relative to length of disease, the X ± SE were grouped into three time periods, 1= 
.1-10yrs; 2= 10.1-20yrs; and 3= 20.1-33yrs.  To compare the three different lengths of 
the disease, a one-way ANOVA and Bonferroni as a post-hoc measure was used to 
compare the three groups (.1-10yrs; 10.1-20yrs; 20.1-33yrs) for each outcome 
measure. ANCOVA was used to compare means of balance measures for the three 
groups based on duration of disease, using age as a covariate.  To evaluate any 
potential relationship between EDSS scores and balance scores, and EDSS scores and 
MSQOL-54 scores Pearson Correlation Coefficients were used for the entire MS 
group and then separated by duration of disease.   
The significance level was set at p ≤ 0.05 and all statistical analysis was 
performed by SPSS 12.0.  
 
RESULTS  
Physical Characteristics                                                                                                  
There was no significant difference in age or height between the MS group 
and the healthy controls (p>0.05). However, there was a significant difference in 
weight between the MS (X = 76.8 ± 2.8) group and healthy controls (X = 64.3 ± 1.6), 
with the MS group being significantly heavier (p = .000) (Table 1). 
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Table 1. Physical Characteristics for healthy controls and MS population 
Parameter Group N X SE P-Value 
Age (yrs) Control   


























** Significant at the 0.01 level 
 
Balance Measures 
There were no significant trial effects for measures with multiple trials on the  
balance measures, so the average of all three trials were used for each measure, with 
the exception of Modified Clinical Test for Sensory Integration of Balance 
(MCTSIB) test with eyes closed.  There was a significant difference between trial 1 
and trial 3, so the average of trials 2 and 3 were averaged and used. 
For unilateral stance (deg/sec) eyes open, eyes closed, tandem walk and 
MCTSIB (deg/sec) a significance difference was seen between the MS group and the 
healthy controls (p<0.01). The MS group had more movement during this activity.  
Small scores are good and indicate little movement whereas larger scores are worse 
and indicate more movement (Table 2).                                        
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Table 2. Balance Measures for Healthy Controls and MS population 
Balance 
measures 
























































** Significant at the 0.01 level 
 
Outcome Measures Based on Duration of Disease                                                                               
In order to examine if the duration of the disease had any effect on the 
different outcome measures, the MS subjects were categorized as group1 (.1-10yrs 
since MS diagnosis); group 2 (10.1-20yrs since MS diagnosis); and group 3 (20.1-
33yrs since MS diagnosis).                                                                           
 Physical characteristics based on duration of disease                                                                                                
The estimated mean age for the individuals with MS was 44 ±1.2 years, and 
the mean duration of disease for the group as a whole was 8.08 ± .96 years (Table 3). 
Table 3. Duration of disease for MS group 
Duration of MS N X SE 
1 = .1-10 yrs 48 4.22 .40 
2 = 10.1-20 yrs 10 14.10 1.01 
3 = 20.1-33 yrs 7 26.00 1.41 
Total 65 8.08 .96 
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When separating the MS population into 3 separate groups based on duration 
of disease, there was a significant difference in age (p = 0.029) between group 1 (X = 
42.1±1.5) and group 3 (X = 52.0±2.3), with group 3 being significantly older than 
group 1 (p = .043).  No difference was found between groups based on the duration of 
disease for height or weight (Table 4). 
 
Table 4. Physical Characteristics Based on Duration of Disease 
 
Parameter Group N X SE P-Value 







































*Significant at p<0.05 
Balance Measures                                                                                                                             
A significant difference was found between groups (p = .002) for unilateral 
stance with eyes open, right leg (deg/sec).  A Bonferroni post hoc found the 
difference to be between group 1 and 3 (p = .009).  This indicates that group 3 (X = 
8.3 ± 2.3) had poorer scores on unilateral stance with eyes open compared to group 1 
(X = 2.8 ± .55).  Further, there was a significant difference (p = .000) found between 
groups on MCTSIB mean on foam surface with eyes open.  Bonferroni post hoc 
analysis indicated that group 1 (X = .67±.03) and group 3 (X = 1.2±.15) were 
significantly different (p = .000).  
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For MCTSIB on firm surface with eyes closed there was also a significant 
difference (p = .015) between group 1 (X = .48 ± .07) and group 2 (X = 1.2 ± .53).  In 
all the conditions, high sway scores are worse and low sway scores are good, 
suggesting better postural balance.  So, for these two tests, people that had been 
diagnosed longer with MS as is group 2 (10.1-20yrs) and group 3 (20.1-33yrs) scored 
worse than people in group 1 that had only been diagnosed with MS for .1-10 yrs.  
For the step up and over (SUO) test for the right leg, there was a significant 
difference (p = .020) between the groups.  Bonferroni post hoc found the difference to 
be between group 1 (X = 1.8±.08) and group 3 (X = 4.80±2.7), (p = .018).  This was 
also the case for the left leg (p = .023), with group 1 (X = 1.7±.06) and group 3 (X = 
4.5±2.5), (p = .019).  Since the subject is asked to do this task as fast as possible, low 
scores indicate fast movement and are better than high scores that indicate slower 
movement.  For both of these tasks the group that had been diagnosed with MS for 
the longest duration was significantly slower than the group that had been diagnosed 
the shortest time.  The ANCOVA results, which utilized age as the covariate did not 
change the original ANOVA findings, based on duration of MS diagnosis for the 
balance measures of unilateral stance eyes open, standing on foam eyes open and 
standing on firm surface with eyes closed.  Only the step up and over test for both 
right and left leg became non-significant (p=.052 and p=.056) respectively following 
the ANCOVA protocol.  This might indicate that the group with the longest MS 
diagnosis was slower than the other two groups due to increased age rather than 
duration of MS. 
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MSQOL-54                                                                                                                    
There was no significant difference between any of the 12 subscales of the 
“The Multiple Sclerosis Quality of Life-54 Instrument” and duration of MS, 
indicating that for this group the length of the disease had no significant impact on 
any aspect of quality of life.  
EDSS                                                                                                                              
The expanded disability status scale was performed by their MS physician and 
the scale takes into account disability or dysfunction according to pyramidal, 
cerebellar, brain stem, sensory, bowel and bladder, visual, cerebral and other 
functions.  Each of these subcomponents was graded from 0-10 depending on the 
severity of the disability, with 0 being normal and indicating no disability and 10 
“death” by MS.  The only subcomponent of the EDSS that had a significant 
difference between the different durations of disease was sensory function (p = .031).  
Bonferroni post hoc analysis indicated that group 1 (X = .22±.06) and group 2 (X = 
.80±.38) were significantly different (p = .040). 
The final part of the statistical analyses involved computing Pearson 
Correlation Coefficients between measures of EDSS (disability) and quality of life 
with measures of balance.  
EDSS and Balance 
The EDSS components range in values from 0 to 10 with low scores 
indicating better function.  Similarly, low balance scores compared to higher values 
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indicated better postural stability.  Therefore it would be expected that the 
relationship between EDSS score and balance scores would be positive.   
In general there were positive, low to moderate relationships between EDSS 
scores and balance measures.  When examining balance measures within the MS 
group based on the duration of disease, the group that had been diagnosed the longest 
(20.1 – 33 years) did worse on the balance tests.  As the length of disease increased 
there were stronger positive correlations between EDSS and balance. 
EDSS and MSQOL-54 
The relationship between EDSS (and their 8 subscales) and MSQOL-54 
(including physical and mental health, and their 12 subscales) was also examined.  
When examining EDSS scores and MSQOL-54, negative correlations were 
expected since low scores on EDSS would indicate low disability and would then 
correspond to a higher score for quality of life.  In general there were negative, low to 
moderate relationships between EDSS scores and MSQOL-54.  
Overall, the mental health composite of the MSQOL-54 increased over 
duration of disease, indicating that the individuals that had had MS the longest also 
had better mental health.  This could be explained by that these individuals have 
come to term with their disease and are doing well.  For physical health composite, 
individuals that had had the disease from 10.1-20 years indicated the worse physical 
health. The “newly” diagnosed group and the group that had had the disease the 
longest had better scores on physical health.  For overall EDDS scores, individuals 
that had the disease for 10.1-20 and 20.1-33 years had the same higher score than the 
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group with the disease for 0.1-10 years, indicating that the groups having the disease 
the longest also was more symptomatic. 
 
DISCUSSION AND CONCLUSION 
There can be several reasons for balance disturbances in individuals with MS.  
The most common source for poor balance in MS is demyelination in the cerebellar 
connections in the brainstem, particularly lesions located in the vestibular nuclei 
(Burks and Johnson, 2000).  Other secondary factors that affect balance are loss of 
proprioception (sensory ataxia), muscle weakness and spasticity.  Loss of 
proprioception is important because that function provides the needed information 
about limb location without actually having to look at them.  Areas of demyelination 
can cause delayed conduction, still allowing the brain to receive input but in a 
delayed fashion. In MS, in addition to demyelination there can be loss of function due 
to loss of conduction capability in some axons from transected axons or neuron cell 
death (Burks and Johnson, 2000).  Muscle weakness is a loss of muscle strength that 
can be caused by damage in the corticospinal tract, which can affect balance and the 
ability to walk.  If there is damage in the corticospinal tract, the level of disability 
depends both on the level and the location of the lesion (Burks and Johnson, 2000).  
Spasticity is generally caused by lesions in the part of the brain or spinal cord that 
controls voluntary movement (Burks and Johnson, 2000).   
The MS group and the healthy control group did not differ in age or height, 
but the MS group was heavier than the healthy control group.  This may be explained 
by a more sedentary lifestyle due to MS related dysfunctions.  Severe fatigue in MS 
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patients, which has been estimated to be as much as 125% more than in healthy 
subjects, could contribute to a sedentary lifestyle in this population 11, and thus more 
weight gain.  
For the balance measures there were also differences found between the two 
groups.  The MS group demonstrated significantly greater sway and movement 
during all balance activities with the exception of step quick turn test, compared to 
healthy controls.  This was expected, as individuals with MS often have trouble with 
postural stability secondary to lesions in the cerebellum or the pathways connecting to 
it.   
When examining balance measures within the MS group, basing it on the 
duration of disease, the group that had the disease the longest did worse on the 
balance tests, demonstrating more sway.  A cross sectional study 18 interviewed each 
participant with MS twice and found that 26 of the 27 people reported loss of balance 
as the most common symptom of their MS and approximately half the group said it 
interfered a lot with their daily activities.  But, there are also several other symptoms 
as a result of MS that can influence postural stability, such as fatigue, weakness, 
numbness, spasticity, tremors, decreased coordination and pain 17.
Quality of life has been widely studied with the MS population using the 
MSQOL-54, which is a questionnaire standardized for MS populations.  Living with a 
chronic immune-mediated disease of the central nervous system that has no cure can 
often lead to decreased quality of life, and depression is frequently seen.  It has been 
widely accepted as a critical and valuable measure for well-being in the MS 
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population 6, 24, 29. For this investigation there were negative correlations between 
EDSS scores and MSQOL-54 scores, indicating that as individuals report higher 
quality of life scores, they also had lower disability scores.  This is in agreement with 
a study by 46, were they reported patients with higher EDSS having reduced quality of 
life scores (HRQoL).  Although there were no significant relationships between 
duration of disease and quality of life in our study similar to Fruehwald et al. (2001), 
others have found that disease duration had a significant effect on mental dimensions 
of quality of life 46.
Kurtzke’s expanded disability status scale (EDSS) is a functional assessment 
heavily based on mobility and does not cover very well other areas of disability and 
health, such as pain, vitality or emotional problems 29, 40. The EDSS measured by a 
physician takes into account disability or dysfunction according to pyramidal, 
cerebellar, brain stem, sensory, bowel and bladder, visual, cerebral and other 
functions.  Each of these components is graded from 0-10 depending on the severity 
of the disability, with 0 being normal and indicating no disability and 10 “death” by 
MS.  The results of this investigation did not show any difference among these sub 
components other than sensory, with group 2 having more disability than group 1. 
Otherwise, there was an increase in disability on all sub components with exception 
for visual and sensory, with group 1 having the lowest scores and group 3 having the 
highest scores, thus indicating more disability as duration of disease increased.  
Disturbances in balance and gait are frequently observed in individuals with 
MS 14 and have been defined as the most common symptom in some individuals 18, 54,
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and seen in as much as 18-63% in MS patients 27. In this investigation, the 
individuals demonstrated a positive correlation on most of the sub-components of the 
EDSS and the balance measures, indicating that with increased dysfunction in the 
various areas of the brain there was also a trend towards more postural imbalance.  
There was a higher score of dysfunction for the pyramidal function than for any other 
area within this group.  However, there was a very low score of dysfunction located 
in the cerebellar area, which is most commonly affected in patients with poor balance.  
When examining this based on duration of disease, the oldest group (Group 3) which 
had the disease the longest also had the highest EDSS, indicating more total 
dysfunction.   
This cross-sectional study investigated overall postural balance in women 
with MS and compared them to healthy controls.  Because this disease is both chronic 
and progressive in nature, it is hard to predict what the future holds for this population 
in regard to their physical abilities, especially without the use of medication.  General 
impairments of mobility can be detrimental to people of any age, but especially in 
older adults and even more for people with disabilities that interfere with daily 
activities.  Previous research have reported balance disturbances in as much as 23-
84% of people with MS 52, with delayed and distorted proprioception being the main 
reason for postural imbalance in individuals with MS 10. Many of these impairments 
can be secondary to motor weakness or numbness, which is seen in up to 80% of 
people with MS 18, 47, or prevalence of profound fatigue in people with MS 11. When 
postural stability is compromised by any of the above factors it can have a detrimental 
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effect on people’s everyday lives and overall quality of life.  With an ongoing and 
progressive worsening of the disease, the ability of maintaining balance to do daily 
tasks such as walking without any assistive devices and everyday chores, the 
individual has to prepare not only physiologically but also psychologically.  It could 
possible affect their ability to maintain their independence and suddenly they may 
have to face the reality of depending on others.  The results of this investigation 
demonstrated that individuals with MS do have increased postural instability 
compared to the healthy population.  Further, it also showed that people diagnosed 
with MS for a longer period of time also demonstrated poorer postural balance than 
people that had not been diagnosed for as long.  Therefore, studies like this and future 
studies are encouraged to gain information that can help with interventions to increase 
balance in individuals with neurological disorders. 
LIMITATIONS OF THE STUDY 
One of the limitations of this study was that it only included women with 
relapsing remitting form of MS, so they were fully ambulatory.  This could affect 
balance measures as a progressive form of MS is much more disabling. Also, 
medications were not controlled for in this study and anti spasticity medication like 
Baclofen is common for MS patients and could have influenced the results.  The 
testing was done at different times for every subject and some subjects may have been 
fatigued at the end of the day, which is very common for people with MS. 
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SUGGESTIONS FOR FUTURE RESEARCH 
Postural balance has been recognized as one of the most common problems 
with MS.  With this study and other studies it has been established that MS patients 
are having more trouble with postural balance compared to the healthy population. 
More studies including both genders should be done to identify the most limiting 
component of balance and interventions including resistance training, stretching, yoga 
and weight training should be implemented in the work out program for these 
individuals so that the quality of life for the MS population could be dramatically 
increased.   
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INSTRUCTIONS:
This survey asks about your health and daily activities. Answer every Question by  
circling the appropriate number (1, 2, 3, ...). 
If you are unsure about how to answer a question, please give the best answer you  
can and write a comment or explanation in the margin. 
Please feel free to ask someone to assist you if you need help reading or marking  
the form. 
1. In general, would you say your health is: 
(circle one number) 
Excellent. . . . . . . . . . . . ., . . . . . . . . . 1
Very good .......................................... 2 
Good.. . . . . . . . . . .. . . . . . . . . . . . . . . 3
Fair. . . .. .. .. . ... . . .. . . . . ., .. . . .. . . ..4
Poor......................................................5
2. Compared to one year ago, how would you rate your health in 
general now?
(circle one number) 
Much better now than one year ago………………...1 
Somewhat better now than one year ago..................2
About the same………………………………………….3
Somewhat worse now than one year ago……………4 
.Much worse now than one year ago………………….5 
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3-12.The following questions are about activities you might do during a typical 
day. Does your health limit you in these activities? If so, how much? 
Circle 1, 2 or 3 on each line)     
Yes, Yes, No, Not 
Limited Limited limited 
a lot a Little a t All 
3. Vigorous activities, such as     
running, lifting heavy  
objects, participating in  
1 2 3
strenuous sports     
4. Moderate activities, such as     
moving a table, pushing a  1 
vacuum cleaner, bowling, or   
2 3
playing golf     
5. Lifting or carrying groceries  1 2 3 
6. Climbing several flights of 
stairs 
1 2 3
7. Climbing one flight of stairs 1 2 3
8. Bending, kneeling, or   
stooping 1 
2 3
9. Walking more than a mile 1 2 3 
10. Walking several blocks 1 2 3 
11. Walking one block 1  2 3 
12. Bathing and dressing  
yourself 
1 2 3
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13-16. During the past 4 weeks, have you had any of the following problems  
with your work or other regular daily activities as a result of your physical health ?
Circle one number on each line)   
YES NO 
13. Cut down on the amount of time you could 
spend on work or other activities 
1 2
14. Accomplished less than you would like 1 2 
15. Were limited in the kind of work or other 
activities 
1 2
16. Had difficulty performing the work or other   
activities 
(for example, it took extra effort) 1 2
17 -19. During the past 4 weeks, have you had any of the following problems with  
your work or other regular daily activities as a result of any emotional problems 
(such as feeling depressed or anxious). 
Circle one number on each line)   
YES NO 
17. Cut down on the amount of time you could 1 2 
spend on work or other activities   
18. Accomplished less than you would like 1 2 
19. Didn’t do work or other activities as carefully 1 2
as usual   
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20. During the past 4 weeks, to what extent has your physical health or  
emotional problems interfered with your normal social activities with family, friends, 
neighbors, or groups? 
(circle one number) 
Not at all.............................................. 1
Slightly ............................................... 2
Moderately ......................................... 3
Quite a bit ........................................... 4
Extremely... ........................................5
Pain
21. How much bodily pain have you had during the past 4 weeks?






Very severe ............................... 6
22. During the past 4 weeks, how much did pain interfere with your 
 normal work (including both work outside the home and housework)?
(circle one number) 
Not at all .....................................1
A little bit.................................... 2
Moderately ................................ 3
Quite a bit.................................. 4
Extremely .................................. 5
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These questions are about how you feel and how things have been with you during the past 4 weeks. For each 
question, please give the one answer that comes closest to the way you have been feeling.
Copyright@ 1995, University of California, Los Angeles 
A Good
Circle one number on each line All Most Bit of Some A Little None 
23-32 of the Of the the of the of the of the 
Time Time Time Time Time Time 
23. Did you feel full of pep? 1 2 3 4 5 6 
24. Have you been a very 
person? 1 2 3 4 5 6
25. Have you felt so down in       
the dumps that nothing 1 2 3 4 5 6 
could cheer you up?       
1 2 3 4 5 626. Have you felt calm and 
peaceful?   
27. Did you have a lot of 1 2 3 4 5 6
energy?  
28. Have you felt downhearted 
and blue? 1 2 3 4 5 6
29. Did you feel worn out? 1 2 3 4 5 6 
30. Have you been a happy  
person? 1 2 3 4 5 6
31. Did you feel tired? 1 2 3 4 5 6 
32. Did you feel rested on waking 
in the morning? 1 2 3 4 5 6
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(circle one number) 
33.During the past 4 weeks, how much of the time has your physical 
health or emotional problems interfered with your social activities (like visiting  
with friends, relatives, etc.)?
All of the time..............................1
Most of the time ......................... 2
Some of the time ....................... 3
A little of the time ....................... 4
None of the time......................... 5
Health in General
34-37. How TRUE or FALSE is each of the following statements for you. 
Circle one number on each line)     
Definitely Mostly Not Mostly Definitely 
True True Sure False False 
34. I seem to get sick  a little 
easier  than other people 1 2 3 4 5
35. I am as healthy  as 
anybody I  know 1 2 3 4 5
36. I expect my      
health to get 1 2 3 4 5 
worse      
37. My health is      
excellent 1 2 3 4 5 
Copyright@ 1995, University of California, Los Angeles 
86
Health Distress
How much of the time during the past 4 weeks... 
Circle one number on each line)       
A Good  
All Most 
Bit of 
Some A Little 
None 
of the of the the of the of the of the 
Time Time Time Time Time Time 
38. Were you discouraged by 
your health problems? 
1 2 3 4 5 6
39. Were you frustrated about 
your health? 
1 2 3 4 5 6
40. Was your health a worry    
in your life? 1 2 3 4 5 6
41. Did you feel weighed       
down by your health 1 2 3 4 5 6 
problems?       
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Cognitive Function 
How much of the time during the past 4 weeks... 
Circle one number on each 
line)  
A Good All Most 
Bit of 
Some A little None 
of the of the the of the of the of the
Time Time Time Time Time Time 
42. Have you had difficulty 
concentrating and thinking? 1 2 3 4 5 6
43. Did you have trouble       
keeping your attention 
on an activity for long? 
1 2 3 4 5 6
44. Have you had trouble 
with your memory? 
1 2 3 4 5 6
45. Have others, such as       
family members or       
friends, noticed that       
you have trouble with 3 4 5 6 
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Sexual Function
Circle one number on each line)    
A Little of Somewhat Very 
Not a a of a Much a 
WOMEN problem Problem Problem Problem 
46. Lack of sexual  
interest 1 2 3 4 
47. Inadequate     
lubrication 1 2 3 4 
48. Difficulty having     
orgasm 1 2 3 4 
49. Ability to satisfy     
sexual partner 1 2 3 4 
46-50. The next set of questions are about your sexual function and your satisfaction with your 
sexual function. Please answer as accurately as possible about your function during  
 the last 4 weeks only. 
How much of a problem was each of the following for you during the past 4 weeks?
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Circle one number on each line)    
A Little of Somewhat Very 
Not a a of a Much a 
MEN problem Problem Problem Problem 
46. Lack of sexual     
interest 1 2 3 4 
47. Difficulty getting     
or keeping an 
erection 
1 2 3 4
48. Difficulty having     
orgasm 1 2 3 4 
49. Ability to satisfy     
sexual partner 1 2 3 4 
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50. Overall, how satisfied were you with your sexual function during the past 4 weeks?
(circle one number) 
Very satisfied ...................................... 1
Somewhat satisfied ............................ 2




51. During the past 4 weeks, to what extent have problems with your bowel or bladder function 
 interfered with your normal social activities with family, friends, neighbors, or groups? 
 (circle one number) 





52. During the past 4 weeks, how much did pain interfere with your enjoyment of life? 
(circle one number) 
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53. Overall, how would you rate your own quality-of-life? 
Circle one number on the scale below: 
10 9 8 7 6 5 4 3 2 1 0 




bad as or worse 
than being dead 
4. Which best describes how you feel about your life as a whole? 
(circle one number) 
Terrible ................................................1
Unhappy .............................................2
Mostly dissatisfied .............................. 3
Mixed - about equally 
satisfied and dissatisfied .................... 4
Mostly satisfied ................................... 5
Pleased............................................... 6
Delighted ............................................ 7
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MSQOL-54 Physical Health Composite Score
Table 3
MSQOL-54 Mental Health Composite Score
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Table 1   
MSQOL-54 Scoring  
Form  
Response Final Score 
Scale/ item Number  1 2 3 4 5 6 Subtotal 0-100 point 
 scale 
Physical Health 3.  0 50 100
4.  0 50 100
5.  0 50 100
6.  0 50 100
7.  0 50 100
8.  0 50 100
9.  0 50 100
10. 0 50 100
11. 0 50 100
12. 0 50 100
Total: ⁄ 10 =
Role limitations due to             
physical problems             





Role limitations due to             
emotional problems             




Pain 21. 100 80 60 40 20 0     
 22. 100 75 50 25 0       
 52. 100 75 50 25 0       
 Total: ⁄ 3=
Emotional well-being             
 24. 0  20 40 60 80 100     
 25. 0  20 40 60 80 100     
 26. 100 80 60 40 20 0     
 28. 0  20 40 60 80 100     
 30. 100 80 60 40 20 0     
 Total: ⁄ 5=
Energy 23. 100 80 60 40 20 0     
 27. 100 80 60 40 20 0
29. 0  20 40 60 80 100     
 31. 0  20 40 60 80 100     
 32. 100 80 60 40 20 0
Total: ⁄ 5=
Table 1 (cont.)     Response Final Score 
Scale/Item Number 1  2 3 4 5 6  Subtotal 0-100 point 
93
Health Perceptions 1. 100 75 50 25  0      
34. 0 25 50 75  100      
35. 100 75 50 25  0      
36. 0 25 50 75  100     




Social function            
20. 100 75 50 25  0      
33. 0 25 50 75  100      
51. 100 75 50 25  0      
 Total: ⁄ 3=
Cognitive function            
42. 0 20 40 60  80 100     
43. 0 20 40 60 80 100     
44. 0 20 40 60  80 100     
45. 0 20 40 60 80 100     
 Total: ⁄ 4=
Health distress  
38. 0 20 40 60 80 100  
39. 0 20 40 60 80 100  
40. 0 20 40 60 80 100  





Sexual function’            
46. 100 66.7 33.3 0        
47. 100 667 33.3 0        
48. 100 66.7 33.3 0        
49. 100 667 33.3 0        
 Total: ⁄ 4=  
Change in health            
2. 100 75 50 25 0      
Satisfaction with sexual function          
 50. 100 75 50 25 0
Response      
Overall quality of life 1 2 3 4 5 6 7
53. (multiply response by 10)       
54. 0 16.7 33.3 50 66.7 83.3 100
Total: ⁄ 2=
Note: The total number of items in each scale is listed as the divisor for each subtotal. However, due to  
missing data,  the divisor might actually be less than that if not every item within a given scale has been  
answered. For example, if  item 38 in the Health Distress scale was left blank and the other 3 items in  
the scale were answered, then the "Total"  score for Health Distress would be divided by '3' (instead of'4') 
 to obtain the "Final Score." * Males and females can be combined in the analysis even though question  
47 is different for the two groups. The scale  scores can also be reported separately for males and females. 
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Table 2      
Formula for calculating MSQOL-54 Physical Health Composite Score   
MSQOl-54 Scale Final Scale Score x Weight = Subtotal





 = Health perceptions  x .17  (b)
 = Energy/fatigue  x .12  ©
=Role limitations - physical  x .12  (d)
Pain  = 
 x. .11  (e)
Sexual function  = 
 x .08  (f)
 = Social function  x .12  (g)
Health distress  x .11 = (h)
PHYSICAL HEALTH COMPOSITE: Sum subtotals (a) through (h) = 
Table 3 
Formula for calculating MSQOL-54 Mental Health Composite Score 
MSQOl-54 Scale Final Scale Score x Weight = Subtotal





 = Overall quality of life  x 18  (b)
 = Emotional well-being  x .29  ©
=Role limitations - emotional  x .24  (d)
 = Cognitive function  x .15  (e)
MENTAL HEALTH COMPOSITE: Sum subtotals (a) through (e) =   
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Informed Consent-Mercy Hospital 
INFORMED CONSENT  
TO PARTICIPATE IN A RESEARCH STUDY 
 
PROJECT TITLE:   COMPARISON OF POSTURAL BALANCE IN WOMEN WITH 
NEUROMUSCULAR DISORDERS AND HEALTHY 
CONTROLS 
PRINCIPAL 
INVESTIGATOR:   
Dr. Michael Bemben 
CONTACT 






Dr. Michael Bemben 
Department of Health and Exercise Science 
1401 Asp Avenue, Room 120, Norman, OK 73019 
Telephone (405) 325-2717 
Email: mgbemben@ou.edu
Cecilie Fjeldstad, PhD Candidate 
Department of Health and Exercise Science 
1401 Asp Avenue, Room 122, Norman, OK 73019 
Telephone (405) 325-5211 
Email: Cecilie.Fjeldstad-1@ou.edu
You are being asked to volunteer for a research study. This study is being conducted 
at Mercy NeuroScience Institute, Oklahoma City, OK and the Department of Health 
and Exercise Science in Norman, OK. You are selected as a possible participant 
because you fit the inclusion criteria.  Please read this form and ask any questions that 
you may have before agreeing to take part in this study.   
Purpose of the Research Study  
The primary purpose of this study is to compare balance in women with neurological  
disorders and healthy controls.  The secondary purpose is to investigate the  
relationship between balance and the EDSS score in patients with neurological  
disorders.  
 
Inclusion Criteria for Subjects with neurological disorder: 
1) Subjects must have been diagnosed with a form of neurological disorder by a 
physician; 2) Subjects have to score 5 or below on the expanded disability status 
scale; 3) Subjects will be fully ambulatory without assistive device; 4) Subjects will 
be of a mental capacity to give written informed consent and comply with the 
proposed protocols; 5) Subjects will consist of females between the ages of 18-64 
years. 
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Inclusion Criteria for Healthy Controls: 
1) Subjects will consist of females between the ages of 18-64 years; 2) Subjects will 
be of a mental capacity to give written informed consent and comply with the 
proposed protocols. 
Exclusion Criteria for Subjects with neurological disorder: 
1) Women not in the age-group 18-64 years; 2) males; 3) Those with a higher score 
than 5 on the expanded disability status scale; 4) Those who are not fully ambulatory; 
and 5) Anyone who knows they are currently pregnant. 
 
Exclusion Criteria for Healthy Controls: 
1) Women not in the age-group 18-64 years; 2) Anyone who knows they are currently 
pregnant; 
3) Anyone with physical disabilities preventing them from being tested (ie. 
orthopedic or arthritic problems) will not be allowed to participate in the study; 4) 
Anyone who participates in vigorous exercise, including a resistance-training 
program, 3 or more times per week.   
Procedures 
If you agree to be in this study, you will be asked to do the following things: 
Time Commitment for Subjects: 
The study will require the following test session: 
1) Balance testing will be done during a single test session, and will take 
approximately 30 minutes to do. 
Subjects with neurological disorder: 
a. I will be required to read and sign an informed consent form before the testing 
takes place. 
b. I will fill out a Multiple Sclerosis Quality of Life-54 instrument (MSQOL-54), 
which is a structured, self-report questionnaire concentrating on physical and mental 
health.   
c. I will obtain medical clearance from my MS physician. 
d. A series of six balance measures will be done at one testing session by using the 
Neurocom Balance Master, which is a computerized postural sway assessment 
device.  This devise is designed to measure postural balance and sway on a firm 
surface as well as on a foam surface, with eyes open and closed.  Instructions will 
be given on the computer screen before the actual testing.  Three trials will be 
performed for each test and qualified personnel will conduct the tests. 
 
Healthy controls: 
a. I will be required to read and sign an informed consent form before the testing 
takes place. 
b. I will be required to read and fill out a Health Status Questionnaire and a PAR-Q.  
c. A series of six balance measures will be done at one testing session by using the 
Neurocom Balance Master, which is a computerized postural sway assessment 
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device.  This devise is designed to measure postural balance and sway on a firm 
surface as well as on a foam surface, with eyes open and closed.  Instructions will be 
given on the computer screen before the actual testing.  Three trials will be performed 
for each test and qualified personnel will conduct the tests. 
 
The subjects do NOT have to pay for this procedure. 
 
Risks and Benefits of Being in the Study 
The study has the following risks: 
You understand that when performing any of the requirements for this project, there 
will be qualified personnel present at all times, but you should be aware of the 
following: 
During the balance testing, some tests include eyes shut, which increase instability, 
and may result in falling, but trained personnel will be there for spotting and safety.  
The benefits to participation are:  No therapeutic value is expected from participating 
in this research. 
Compensation 
You will not be reimbursed for your time and participation in this study.  In case of  
injury or illness resulting from this study, emergency medical treatment is available.   
However, you or your insurance company will be expected to pay the usual charge  
from this treatment.  The University of Oklahoma Norman Campus has set no funds,  
to compensate you in the event of injury. 
 
Confidentiality 
The records of this study will be kept private.  In published reports, there will be no 
information included that will make it possible to identify the research participant.  
Research records will be stored securely.  Confidentiality will be maintained by 
coding all information with individual identification numbers. The master list will be 
kept in a locked file cabinet in the Co-PI’s (Cecilie Fjeldstad’s) office. Only qualified 
research personnel and University of Oklahoma Institutional Review Board (IRB) 
will have access to the database containing study information.  All data from the 
study will be entered into statistical analyses and publication reports will refer to 
group mean data.  No individual or group other than the research team will be given 
this information, unless specifically requested by the subject. All subject-related 
materials and data will be held confidential and will be stored in the Co-PI’s records 
for a period no less than 5 years.  After this time, all subject-related materials and data 
will be destroyed and only approved researchers will have access to the records. It 
will not be necessary for the researcher to review the medical records of the subjects.  
Voluntary Nature of the Study 
Participation in this study is voluntary.  Your decision whether or not to participate 
will not result in penalty or loss of benefits to which you are otherwise entitled.  If 
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you decide to participate, you are free to not answer any question or withdraw at any 
time.   
 
Contacts and Questions:   
The researcher(s) conducting this study can be contacted at Cecilie Fjeldstad, 
University of Oklahoma, Department of Health and Exercise Science, 1401 Asp 
Avenue, Room 122, Norman, OK 73019. Telephone (405) 325-5211, E-mail: 
Cecilie.Fjeldstad-1@ou.edu OR Dr. Michael Bemben 
Department of Health and Exercise Science, 1401 Asp Avenue, Room 120, Norman, 
OK 73019. 
Telephone (405) 325-2717.  Email: mgbemben@ou.edu
Co-Investigator’s phone number, Cecilie Fjeldstad, (405)326-9053.  You are 
encouraged to contact the researcher if you have any questions.   
If you have any questions about your rights as a research participant, you may contact 
the University of Oklahoma – Norman Campus Institutional Review Board (OU-NC 
IRB) at (405)325-8110 or irb@ou.edu. Mercy Health System, Oklahoma City, OK, 
IRB. Telephone (405) 752-3694. 
You will be given a copy of this information to keep for your records.  If you are not 
given a copy of this consent form, please request one. 
STATEMENT OF CONSENT 
I have read the above information.  I have asked questions and have received 






Informed Consent-University of Oklahoma 
INFORMED CONSENT  
TO PARTICIPATE IN A RESEARCH STUDY 
 
PROJECT TITLE:   COMPARISON OF POSTURAL BALANCE IN 
WOMEN WITH NEUROMUSCULAR DISORDERS 
AND HEALTHY CONTROLS 
PRINCIPAL 
INVESTIGATOR:   
Dr. Michael Bemben 
CONTACT 






Dr. Michael Bemben 
Department of Health and Exercise Science 
1401 Asp Avenue, Room 120, Norman, OK 73019 
Telephone (405) 325-2717 
Email: mgbemben@ou.edu
Cecilie Fjeldstad, PhD Candidate 
Department of Health and Exercise Science 
1401 Asp Avenue, Room 122, Norman, OK 73019 
Telephone (405) 325-5211 
Email: Cecilie.Fjeldstad-1@ou.edu
You are being asked to volunteer for a research study. This study is being conducted 
at Mercy NeuroScience Institute, Oklahoma City, OK and the Department of Health 
and Exercise Science in Norman, OK. You are selected as a possible participant 
because you fit the inclusion criteria.  Please read this form and ask any questions that 
you may have before agreeing to take part in this study.   
 
Purpose of the Research Study  
The primary purpose of this study is to compare balance in women with neurological 
disorders and healthy controls.  The secondary purpose is to investigate the 




If you agree to be in this study, you will be asked to do the following things: 
Time Commitment for Subjects: 
The study will require the following test session: 
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1) Balance testing will be done during a single test session, and will take 
approximately 30 minutes to do. 
Subjects with neurological disorder: 
a. You will be required to read and sign an informed consent form before the testing 
takes place. 
b. You will be required to read and fill out a Multiple Sclerosis Quality of Life-54 
instrument (MSQOL-54), which is a structured, self-report questionnaire 
concentrating on physical and mental health.   
c. You will obtain medical clearance from your MS physician. 
d. A series of six balance measures will be done at one testing session by using the 
Neurocom Balance Master, which is a computerized postural sway assessment 
device.  This devise is designed to measure postural balance and sway on a firm 
surface as well as on a foam surface, with eyes open and closed.  Instructions will be 
given on the computer screen before the actual testing.  Three trials will be performed 
for each test and qualified personnel will conduct the tests. 
 
Healthy controls: 
a. You will be required to read and sign an informed consent form before the testing 
takes place. 
b. You will be required to read and fill out a Health Status Questionnaire and a PAR-
Q.  
c. A series of six balance measures will be done at one testing session by using the 
Neurocom Balance Master, which is a computerized postural sway assessment 
device.  This devise is designed to measure postural balance and sway on a firm 
surface as well as on a foam surface, with eyes open and closed.  Instructions will be 
given on the computer screen before the actual testing.  Three trials will be performed 
for each test and qualified personnel will conduct the tests. 
 
The subjects do NOT have to pay for this procedure. 
 
Risks and Benefits of Being in the Study 
The study has the following risks: 
You understand that when performing any of the requirements for this project, there 
will be qualified personnel present at all times, but you should be aware of the 
following: 
During the balance testing, some tests include eyes shut, which increase instability, 
and may result in falling, but trained personnel will be there for spotting and safety.  
The benefits to participation are: 
No therapeutic value is expected from participating in this research. 
Compensation 
You will not be reimbursed for your time and participation in this study.  In case of 
injury or illness resulting from this study, emergency medical treatment is available.  
However, you or your insurance company may be expected to pay the usual charge 
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from this treatment.  The University of Oklahoma Norman Campus has set no funds, 
to compensate you in the event of injury. 
 
Confidentiality 
The records of this study will be kept private.  In published reports, there will be no 
information included that will make it possible to identify the research participant.  
Research records will be stored securely.  Confidentiality will be maintained by 
coding all information with individual identification numbers. The master list will be 
kept in a locked file cabinet in the Co-PI’s (Cecilie Fjeldstad’s) office. Only qualified 
research personnel and University of Oklahoma Institutional Review Board (IRB) 
will have access to the database containing study information.  All data from the 
study will be entered into statistical analyses and publication reports will refer to 
group mean data.  No individual or group other than the research team will be given 
this information, unless specifically requested by the subject. All subject-related 
materials and data will be held confidential and will be stored in the Co-PI’s records 
for a period no less than 5 years.  After this time, all subject-related materials and data 
will be destroyed and only approved researchers will have access to the records. It 
will not be necessary for the researcher to review the medical records of the subjects.  
 
Voluntary Nature of the Study 
Participation in this study is voluntary.  Your decision whether or not to participate 
will not result in penalty or loss of benefits to which you are otherwise entitled.  If 
you decide to participate, you are free to not answer any question or withdraw at any 
time.   
 
Contacts and Questions:   
The researcher(s) conducting this study can be contacted at Cecilie Fjeldstad, 
University of Oklahoma, Department of Health and Exercise Science, 1401 Asp 
Avenue, Room 122, Norman, OK 73019. Telephone (405) 325-5211, E-mail: 
Cecilie.Fjeldstad-1@ou.edu OR Dr. Michael Bemben 
Department of Health and Exercise Science, 1401 Asp Avenue, Room 120, Norman, 
OK 73019. 
Telephone (405) 325-2717.  Email: mgbemben@ou.edu
Co-Investigator’s phone number, Cecilie Fjeldstad, (405)326-9053.  You are 
encouraged to contact the researcher if you have any questions.   
If you have any questions about your rights as a research participant, you may contact 
the University of Oklahoma – Norman Campus Institutional Review Board (OU-NC 
IRB) at (405)325-8110 or irb@ou.edu. Mercy Health System, Oklahoma City, OK, 
IRB. Telephone (405) 752-3694. 
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You will be given a copy of this information to keep for your records.  If you are not 
given a copy of this consent form, please request one. 
 
STATEMENT OF CONSENT 
I have read the above information.  I have asked questions and have received 











Diagnosis?                                                                
______________________________ 
 
5 or less on EDSS?                                                   Yes____                      No______ 
 
Fully ambulatory without                                          Yes____                     No_______ 
Assistive device? 
 
Medicine                                                                     Yes____                     
No_______ 
 
If Yes, what type?                                            
___________________________ 
 
Duration of Disease (years)                                         ________ 
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Flyer Healthy Controls 
University of Oklahoma 
Department of Health and Exercise Science 
 
Comparison of Balance in Women with Neuromuscular Disorders and Healthy 
Controls 
 
Study Needing Female Volunteers 
Women: Ages 18-64 years 
 
Total Time Commitment about 1 hour.  Find out your: 
Postural Stability (Balance) 
 
For information contact Michael Bemben, Ph.D: 405-325-2717 or e-mail: 
mgbemben@ou.edu
OR Cecilie Fjeldstad: 405-325-5211 or e-mail: Cecilie.Fjeldstad-1@ou.edu
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PAR – Q & YOU 
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EDSS steps 1.0 to 4.5 refer to people with MS who are fully ambulatory. EDSS steps 
5.0 to 9.5 are defined by the impairment to ambulation.  
 
Kurtzke Expanded Disability Status Scale 
0.0 Normal neurological examination 
1.0 No disability, minimal signs in one FS 
1.5 No disability, minimal signs in more than one FS 
2.0 Minimal disability in one FS 
2.5 Mild disability in one FS or minimal disability in two FS 
3.0 Moderate disability in one FS, or mild disability in three or four FS. Fully ambulatory 
3.5 Fully ambulatory but with moderate disability in one FS and more than minimal disability in 
several others 
4.0 Fully ambulatory without aid, self-sufficient, up and about some 12 hours a day despite relatively 
severe disability; able to walk without aid or rest some 500 meters 
4.5 Fully ambulatory without aid, up and about much of the day, able to work a full day, may 
otherwise have some limitation of full activity or require minimal assistance; characterized by 
relatively severe disability; able to walk without aid or rest some 300 meters. 
5.0 Ambulatory without aid or rest for about 200 meters; disability severe enough to impair full daily 
activities (work a full day without special provisions) 
5.5 Ambulatory without aid or rest for about 100 meters; disability severe enough to preclude full 
daily activities 
6.0 Intermittent or unilateral constant assistance (cane, crutch, brace) required to walk about 100 
meters with or without resting 
6.5 Constant bilateral assistance (canes, crutches, braces) required to walk about 20 meters without 
resting 
7.0 Unable to walk beyond approximately five meters even with aid, essentially restricted to 
wheelchair; wheels self in standard wheelchair and transfers alone; up and about in wheelchair 
some 12 hours a day 
7.5 Unable to take more than a few steps; restricted to wheelchair; may need aid in transfer; wheels 
self but cannot carry on in standard wheelchair a full day; May require motorized wheelchair 
8.0 Essentially restricted to bed or chair or perambulated in wheelchair, but may be out of bed itself 
much of the day; retains many self-care functions; generally has effective use of arms 
8.5 Essentially restricted to bed much of day; has some effective use of arms retains some self care 
functions 
9.0 Confined to bed; can still communicate and eat. 
9.5 Totally helpless bed patient; unable to communicate effectively or eat/swallow 
10.0 Death due to MS 
http://www.mult-sclerosis.org/expandeddisabilitystatusscale.html
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RAW DATA SET 
id age ht wt group agegrp foamec uscogeor uscecr uscoeol
4 19.8 162.0 70.9 1 1 .90 .60 3.10 . 
5 20.2 175.0 59.1 1 1 1.50 .90 1.90 . 
8 21.0 167.0 59.8 1 1 1.00 .80 1.45 . 
9 21.1 152.0 45.0 1 1 1.20 .85 1.65 . 
10 21.7 168.5 64.6 1 1 1.50 .90 1.70 . 
11 21.2 172.0 65.7 1 1 1.00 .85 1.55 . 
12 22.0 168.0 52.6 1 1 1.20 .75 1.75 . 
17 19.9 167.0 63.6 1 1 1.00 .75 1.60 . 
18 20.2 157.0 56.7 1 1 .80 .85 1.25 . 
19 19.3 167.5 76.7 1 1 .80 .70 1.45 . 
21 22.0 162.5 69.1 1 1 1.50 1.00 2.25 . 
23 19.6 165.5 67.0 1 1 1.00 .70 1.40 . 
24 19.6 166.0 56.7 1 1 2.50 .95 2.15 . 
26 22.8 164.0 58.4 1 1 .80 .55 1.20 . 
28 19.5 157.0 55.4 1 1 .80 .85 2.00 . 
29 20.3 168.0 53.4 1 1 1.60 .90 2.35 . 
32 45.8 162.5 65.1 1 2 1.70 .75 1.65 . 
33 44.4 162.5 59.1 1 2 .70 .65 1.30 . 
40 36.9 162.0 52.7 1 2 1.40 1.00 1.75 . 
41 42.0 161.0 75.5 1 2 .90 .90 2.10 . 
43 44.9 168.0 76.3 1 2 1.00 .75 1.60 . 
46 43.0 163.5 53.0 1 2 1.50 .80 1.85 . 
47 39.7 161.0 53.2 1 2 1.10 .75 1.45 . 
48 37.5 164.5 61.6 1 2 1.00 1.05 2.25 . 
50 41.0 157.0 61.8 1 2 2.10 1.00 1.60 . 
52 39.6 171.0 58.5 1 2 .90 .65 1.30 . 
54 40.3 171.0 86.6 1 2 2.00 .95 1.75 . 
56 42.1 161.0 66.5 1 2 .80 1.40 2.15 . 
58 58.3 173.5 92.0 1 3 1.40 1.40 2.10 . 
59 62.2 153.0 61.3 1 3 .90 .95 2.05 . 
60 60.1 160.0 61.0 1 3 1.50 1.05 2.15 . 
61 56.7 159.5 53.4 1 3 1.90 1.50 2.75 . 
62 59.3 156.0 74.7 1 3 1.40 1.05 1.85 . 
64 57.4 162.5 71.0 1 3 1.30 .85 1.35 . 
65 55.7 167.5 69.7 1 3 .90 .95 1.40 . 
66 57.7 169.0 78.0 1 3 1.00 .80 1.65 . 
67 55.9 168.0 66.1 1 3 1.10 1.05 1.85 . 
69 63.3 172.0 55.8 1 3 1.30 1.00 1.30 . 
70 62.0 165.0 52.4 1 3 1.80 1.15 1.70 . 
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id age ht wt group agegrp foamec uscogeor uscecr Uscoeol
71 59.2 164.0 57.2 1 3 1.30 1.05 1.45 . 
73 55.7 156.0 50.2 1 3 1.00 .85 1.60 . 
80 55.6 172.0 66.4 1 3 1.20 1.25 2.95 . 
82 56.7 167.0 86.7 1 3 .80 1.05 1.50 . 
83 60.7 158.5 62.3 1 3 1.70 1.05 2.20 . 
84 55.3 159.5 90.4 1 3 1.00 2.00 4.00 . 
86 35.0 164.0 65.5 2 2 .95 1.13 12.00 .93 
87 47.0 185.5 129.1 2 2 . . . .
88 31.0 160.0 79.1 2 1 1.20 12.00 12.00 .60 
89 43.0 157.0 66.8 2 2 1.65 1.07 12.00 .87 
90 50.0 145.0 69.1 2 3 2.30 1.03 12.00 1.13 
91 48.0 175.0 57.7 2 2 6.00 12.00 . . 
93 49.0 161.0 88.6 2 2 .85 .97 12.00 1.10 
94 40.0 172.5 85.5 2 2 .75 .67 4.90 .63 
95 39.0 169.0 70.5 2 2 1.25 .83 8.67 4.67 
96 32.0 160.5 103.2 2 1 .75 .70 12.00 4.50 
97 22.0 156.0 111.3 2 1 .65 .80 12.00 .80 
98 45.0 171.0 62.7 2 2 1.00 .70 12.00 .73 
99 42.0 161.0 70.5 2 2 1.30 12.00 12.00 .93 
100 51.0 154.0 64.7 2 3 . . . . 
101 41.0 156.0 75.5 2 2 .90 . . . 
102 49.0 152.0 69.5 2 2 6.00 . . . 
103 58.0 168.5 122.7 2 3 . . . .
104 29.0 170.0 82.7 2 1 .85 .77 12.00 .63 
106 42.0 162.5 72.3 2 2 1.65 .77 12.00 1.00 
109 43.0 167.0 99.0 2 2 1.00 1.03 12.00 1.50 
110 52.0 150.0 48.6 2 3 1.35 .77 12.00 .70 
111 50.0 158.0 50.5 2 3 1.60 8.67 . 12.00 
112 50.0 163.5 80.0 2 3 1.10 1.07 12.00 8.27 
113 51.0 164.5 53.2 2 3 . . . . 
114 45.0 164.0 77.3 2 2 1.10 4.80 12.00 4.93 
115 38.0 165.0 99.5 2 2 4.60 8.60 . 8.80 
116 30.0 161.5 83.6 2 1 1.10 .73 12.00 1.03 
117 36.0 155.0 51.8 2 2 .70 1.00 12.00 .83 
118 44.0 161.0 58.2 2 2 1.35 .63 12.00 .70 
119 34.0 156.0 80.5 2 1 1.45 .93 . .80 
120 51.0 170.0 66.8 2 3 2.85 12.00 12.00 12.00 
121 56.0 165.0 90.9 2 3 6.00 12.00 12.00 12.00 
122 35.0 165.0 67.3 2 2 1.40 4.67 12.00 5.03 
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123 50.0 169.0 65.9 2 3 1.75 .73 5.53 .83 
124 52.0 161.5 69.1 2 3 1.45 .97 12.00 .73 
125 54.0 166.5 76.4 2 3 .85 .53 12.00 .67 
126 36.0 164.0 103.4 2 2 1.35 1.00 8.83 .93
127 62.0 160.0 50.4 2 3 2.00 1.53 12.00 12.00 
128 63.0 172.0 109.5 2 3 1.45 12.00 12.00 4.97 
129 45.0 180.0 160.0 2 2 .85 . . .
130 22.0 175.0 52.2 2 1 1.65 4.77 12.00 1.60 
131 46.0 169.0 68.1 2 2 3.70 8.27 . .90 
132 61.0 165.0 92.2 2 3 .85 1.03 12.00 .93 
133 39.0 149.0 46.3 2 2 1.20 .80 8.63 .87 
135 36.0 167.0 123.6 2 2 1.25 8.27 12.00 1.17 
136 20.0 145.0 44.0 2 1 .80 .67 8.37 .93 
137 34.0 167.0 63.1 2 1 1.55 1.13 12.00 1.10 
138 48.0 162.0 56.3 2 2 . 12.00 12.00 12.00 
139 46.0 167.0 67.7 2 2 .80 .73 8.47 1.07 
140 38.0 170.5 56.3 2 2 . 1.03 12.00 8.40 
141 26.0 173.5 128.1 2 1 .45 4.37 12.00 4.73 
142 52.0 164.0 54.5 2 3 1.40 12.00 12.00 1.00 
144 39.0 167.5 78.6 2 2 1.85 .90 12.00 5.00 
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. 1.60 16.35 . . . . . . .
. 2.70 23.10 . . . . . . .
. 1.20 20.10 . . . . . . .
. 2.70 13.50 . . . . . . .
. 1.60 17.40 . . . . . . .
. 3.60 17.30 . . . . . . .
. 3.20 16.75 . . . . . . .
. 4.00 22.05 . . . . . . .
. 2.90 24.55 . . . . . . .
. 2.70 15.75 . . . . . . .
. 3.40 19.40 . . . . . . .
. 2.90 11.35 . . . . . . .
. 3.30 24.05 . . . . . . .
. 2.20 19.05 . . . . . . .
. 5.40 21.85 . . . . . . .
. 2.80 17.15 . . . . . . .
. 2.80 29.50 . . . . . . .
. 2.80 17.15 . . . . . . .
. 4.50 22.20 . . . . . . .
. 2.70 11.00 . . . . . . .
. 3.90 17.90 . . . . . . .
. 4.00 20.20 . . . . . . .
. 2.40 20.70 . . . . . . .
. 4.70 18.75 . . . . . . .
. 5.00 14.05 . . . . . . .
. 3.00 16.10 . . . . . . .
. 3.00 12.05 . . . . . . .
. 3.50 24.85 . . . . . . .
. 2.80 16.50 . . . . . . .
. 4.20 30.25 . . . . . . .
. 3.00 23.75 . . . . . . .
. 5.40 19.75 . . . . . . .
. 3.70 18.35 . . . . . . .
. 3.20 16.90 . . . . . . .
. 4.10 23.45 . . . . . . .
. 1.50 20.45 . . . . . . .
. 2.60 19.65 . . . . . . .
. 1.50 24.90 . . . . . . .
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. 2.30 24.15 . . . . . . .
. 4.90 28.35 . . . . . . .
. 1.40 21.05 . . . . . . .
. 3.70 26.50 . . . . . . .
. 2.70 18.65 . . . . . . .
. 4.60 17.25 . . . . . . .
. 3.50 21.35 . . . . . . .
8.63 4.90 15.17 19.80 . .83 .57 .13 1.53 2.54 
. . . 29.73 . . .40 6.00 . .
12.00 4.37 21.63 13.43 . .47 .43 .47 2.58 1.88 
8.53 2.43 14.70 22.77 . .60 .30 .20 2.49 1.91 
12.00 4.00 15.37 23.03 . .70 .97 .73 1.50 1.70 
. 5.13 14.30 15.87 . 1.77 1.13 1.20 1.75 2.01
12.00 4.00 14.43 22.07 . .50 .40 .23 1.63 1.79 
8.43 4.03 24.20 23.67 . .57 .20 .20 1.35 1.18 
8.40 4.40 19.37 23.43 . .67 1.03 .47 1.73 1.87 
12.00 24.13 11.60 9.83 . .27 .17 .30 1.40 1.65 
8.90 2.47 16.00 16.63 . .63 .33 .27 1.99 2.36 
12.00 2.60 13.87 9.90 . .53 .33 .37 1.54 1.52 
12.00 4.60 16.57 12.33 . .60 .40 .37 1.83 1.75 
. . 18.50 36.37 . . .70 1.03 . .
. . 27.80 34.47 . 1.00 .37 .67 . .
. . 20.33 27.87 . .63 .53 .80 1.98 1.77
. . . . . . .43 .47 . .
12.00 3.63 14.27 17.03 . .43 .23 .33 1.36 1.52 
12.00 5.83 11.67 17.43 . .67 .30 .37 1.48 1.41 
12.00 5.73 19.97 14.93 . .50 .73 .30 1.83 1.84 
12.00 4.17 34.40 44.73 . 1.17 .40 .47 1.40 1.37 
. 5.33 22.20 24.60 . 1.10 .40 .43 2.89 2.19
12.00 3.10 13.53 18.37 . .47 .47 .43 1.56 1.50 
. 7.83 21.87 29.83 . 1.27 .47 .57 2.80 2.44
12.00 2.70 17.20 12.70 . .70 .33 .60 1.78 1.79 
. 6.93 22.37 32.10 . 1.17 1.00 1.50 . .
12.00 6.13 . . . .47 .40 .20 1.19 1.06 
12.00 4.47 20.17 17.17 . .47 .57 .30 1.72 1.63 
12.00 5.37 20.67 26.30 . .53 .40 .20 1.48 1.87 
. 4.60 27.00 27.00 . .63 .37 .47 1.91 1.68
12.00 19.00 21.40 . . 1.70 .70 .97 . . 
12.00 3.03 30.30 16.80 . .80 .37 3.37 2.44 1.75 
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12.00 4.50 15.13 23.03 . .83 .30 .30 1.86 1.70 
8.80 2.87 19.90 15.27 . .53 .17 .30 1.63 1.74 
12.00 1.73 24.97 21.70 . .80 .40 .73 2.20 1.75 
12.00 3.27 15.80 16.73 . .47 .33 .33 1.41 1.36 
12.00 2.37 9.83 11.17 . .60 .30 .40 1.86 1.92 
12.00 3.13 34.23 23.77 . 1.03 .83 1.07 1.56 1.33 
12.00 5.50 13.97 34.53 . 1.13 .20 .43 2.73 2.50 
. . 22.43 18.20 . .73 .70 .40 . .
8.93 4.03 31.90 24.67 . 1.23 .57 .47 1.24 1.38 
. 2.87 16.57 21.77 . 1.00 .53 .27 1.50 1.50
12.00 3.17 16.57 19.73 . .90 .47 .73 2.12 2.42 
1.53 5.97 24.53 24.23 . .53 .27 .33 1.33 1.26 
12.00 3.87 22.20 11.20 . .53 .37 .43 2.10 1.93 
8.60 3.10 14.27 16.20 . .57 .30 .40 1.83 1.50 
8.73 2.00 12.27 15.83 . .67 .27 .23 1.82 1.72 
12.00 7.50 21.23 19.73 . 1.67 1.17 1.70 21.23 19.73 
12.00 4.67 14.40 16.90 . .67 .33 .50 1.57 1.29 
12.00 6.13 19.83 19.80 . .47 .40 .30 3.12 3.07 
12.00 3.20 9.23 16.17 . .33 .17 .17 1.56 1.56 
12.00 5.50 26.07 16.53 . .63 .30 .37 2.45 . 
12.00 3.83 14.37 9.80 . .93 .47 .67 1.52 1.94 
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. . . . . . . .
. . . . . . . .
. . . . . . . .
. . . . . . . .
. . . . . . . .
. . . . . . . .
. . . . . . . .
1 13.00 2.00 95.00 70.00 44.00 100.00 100.00 100.00 
1 13.00 2.00 25.00 87.50 32.00 100.00 55.00 100.00 
1 7.50 1.00 70.00 75.00 56.00 100.00 100.00 91.67 
1 2.00 1.00 50.00 40.00 32.00 .00 21.66 75.00 
1 4.00 1.00 40.00 15.00 4.00 .00 23.33 91.67 
1 24.00 3.00 35.00 30.00 44.00 50.00 63.33 83.35 
1 8.00 1.00 95.00 60.00 32.00 100.00 78.33 25.00 
1 4.50 1.00 80.00 40.00 4.00 50.00 55.00 83.35 
1 7.00 1.00 10.00 35.00 .00 .00 6.66 33.32 
1 3.00 1.00 85.00 45.00 8.00 75.00 53.33 .00 
2 4.00 1.00 95.00 55.00 68.00 100.00 100.00 91.67 
1 1.50 1.00 5.00 60.00 56.00 100.00 63.33 83.32 
1 12.00 2.00 75.00 55.00 8.00 100.00 100.00 100.00 
1 4.00 1.00 10.00 55.00 40.00 .00 85.00 8.32 
1 2.00 1.00 30.00 35.00 32.00 75.00 83.33 75.00 
1 20.00 2.00 65.00 55.00 24.00 .00 46.66 66.67 
5.00 1.00 35.00 55.00 12.00 .00 16.66 50.00 
2 2.00 1.00 60.00 30.00 24.00 25.00 46.66 75.00 
1 5.00 1.00 90.00 60.00 68.00 75.00 61.66 100.00 
. . . . . . . .
1 1.00 1.00 95.00 70.00 60.00 50.00 70.00 49.97 
1 10.00 1.00 65.00 65.00 48.00 .00 85.00 .00 
1 3.00 1.00 55.00 40.00 60.00 75.00 100.00 25.00 
1 1.00 1.00 95.00 40.00 52.00 100.00 91.66 50.00 
1 22.00 3.00 61.11 90.00 72.00 33.33 93.33 50.00 
1 7.00 1.00 15.00 35.00 64.00 .00 38.33 24.97 
2 12.50 2.00 90.00 85.00 16.00 50.00 30.00 8.32 
1 2.00 1.00 15.00 60.00 48.00 75.00 93.33 91.67 
1 2.50 1.00 100.00 40.00 68.00 100.00 70.00 91.67 
1 1.30 1.00 70.00 35.00 20.00 25.00 46.66 75.00 
1 1.50 1.00 90.00 45.00 56.00 100.00 100.00 83.35 
1 14.50 2.00 30.00 55.00 52.00 100.00 100.00 100.00 
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1 7.00 1.00 20.00 70.00 8.00 .00 38.33 25.00 
1 5.00 1.00 60.00 40.00 56.00 50.00 46.66 .00 
1 3.00 1.00 120.00 80.00 16.00 100.00 93.33 50.00 
2 28.00 3.00 90.00 70.00 56.00 100.00 63.33 58.32 
1 5.00 1.00 95.00 60.00 68.00 100.00 93.33 . 
1 10.00 1.00 90.00 70.00 36.00 100.00 100.00 41.67 
2 12.00 2.00 65.00 45.00 40.00 .00 68.33 24.97 
1 10.00 1.00 45.00 55.00 40.00 .00 36.66 75.00 
1 8.00 1.00 60.00 45.00 48.00 .00 76.66 58.32 
2 .10 1.00 75.00 75.00 64.00 .00 76.66 91.67 
1 10.00 1.00 90.00 40.00 36.00 100.00 85.00 91.67 
1 20.00 2.00 30.00 70.00 40.00 .00 46.66 . 
1 5.50 1.00 100.00 75.00 32.00 100.00 93.33 91.67 
1 12.00 2.00 55.00 30.00 16.00 75.00 23.33 .00 
1 1.50 1.00 80.00 25.00 16.00 25.00 46.66 83.35 
1 6.00 1.00 95.00 75.00 72.00 100.00 76.66 100.00 
1 23.00 3.00 55.00 85.00 80.00 100.00 100.00 83.35 
1 25.00 3.00 95.00 70.00 40.00 75.00 70.00 41.65 
1 9.00 1.00 40.00 30.00 32.00 75.00 31.66 33.30 
1 1.00 1.00 85.00 55.00 16.00 50.00 61.66 58.35 
1 3.00 1.00 15.00 40.00 48.00 .00 78.33 16.65 
1 1.00 1.00 60.00 40.00 28.00 .00 46.66 66.67 
1 2.50 1.00 45.00 70.00 16.00 25.00 85.00 41.65 
1 2.50 1.00 60.00 65.00 48.00 100.00 70.00 75.02 
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. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
100.00 . . . . . . . . 
75.00 80.00 85.13 80.00 90.00 84.00 100.00 90.00 89.26 
100.00 75.00 66.26 75.00 50.00 64.00 100.00 85.00 74.81 
41.66 80.00 82.50 80.00 86.65 80.00 100.00 85.00 86.74 
33.33 45.00 37.46 45.00 53.35 88.00 100.00 75.00 76.67 
87.50 .00 23.72 .00 45.00 28.00 .00 15.00 18.47 
100.00 80.00 55.25 80.00 81.65 84.00 100.00 70.00 84.75 
66.66 100.00 75.80 100.00 81.65 56.00 100.00 75.00 80.18 
8.33 80.00 56.38 80.00 55.00 56.00 .00 25.00 86.37 
50.00 .00 12.04 .00 18.35 .00 .00 .00 4.46 
91.66 80.00 52.72 80.00 73.35 60.00 .00 45.00 48.55 
100.00 80.00 83.78 80.00 73.35 80.00 100.00 50.00 79.10 
100.00 65.00 62.54 65.00 78.35 84.00 100.00 75.00 82.81 
75.00 60.00 72.66 60.00 81.65 76.00 100.00 75.00 80.38 
91.66 40.00 39.26 40.00 80.00 92.00 100.00 55.00 78.93 
75.00 55.00 56.09 55.00 60.00 52.00 30.00 80.00 52.78 
41.66 30.00 46.04 30.00 70.00 56.00 .00 25.00 36.79 
58.33 70.00 35.26 70.00 30.00 68.00 100.00 60.00 67.92 
83.33 35.00 43.12 35.00 63.35 80.00 100.00 55.00 71.75 
. 60.00 73.94 60.00 76.65 60.00 66.66 90.00 68.99 
100.00 . . . . . . . . 
83.33 80.00 73.74 80.00 78.35 76.00 100.00 60.00 80.34 
41.66 85.00 56.55 85.00 71.65 68.00 .00 80.00 56.51 
83.33 80.00 59.14 80.00 33.35 80.00 .00 55.00 48.65 
83.33 50.00 70.76 50.00 73.35 76.00 66.66 80.00 70.23 
16.66 85.00 71.91 85.00 73.35 100.00 100.00 85.00 90.85 
58.33 70.00 32.07 70.00 81.65 76.00 .00 55.00 54.78 
66.66 55.00 54.67 55.00 50.00 72.00 .00 10.00 52.58 
83.33 10.00 64.09 10.00 65.00 52.00 100.00 80.00 76.78 
66.66 75.00 77.23 75.00 81.65 84.00 100.00 85.00 86.30 
100.00 55.00 48.42 55.00 68.35 48.00 100.00 40.00 63.92 
83.33 70.00 79.03 70.00 81.65 76.00 100.00 85.00 83.28 
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33.33 85.00 71.03 85.00 100.00 96.00 100.00 90.00 95.24 
91.66 80.00 35.26 80.00 76.65 80.00 .00 50.00 55.69 
91.66 100.00 56.84 100.00 81.65 96.00 100.00 100.00 95.53 
91.66 80.00 81.97 80.00 81.65 84.00 100.00 55.00 82.50 
91.66 80.00 77.33 80.00 86.65 88.00 100.00 85.00 89.06 
91.60 55.00 73.81 55.00 73.35 72.00 100.00 80.00 77.78 
50.00 60.00 75.44 60.00 81.65 68.00 33.33 55.00 59.05 
75.00 80.00 47.80 80.00 60.00 80.00 100.00 70.00 79.70 
33.33 85.00 116.30 85.00 81.65 60.00 100.00 15.00 70.24 
91.66 60.00 47.29 60.00 105.00 60.00 .00 15.00 46.95 
83.33 55.00 65.98 55.00 68.35 64.00 .00 55.00 46.81 
50.00 60.00 71.69 60.00 63.35 64.00 100.00 75.00 73.61 
100.00 95.00 43.35 95.00 100.00 60.00 33.33 80.00 68.60 
66.66 100.00 86.18 100.00 73.35 72.00 100.00 55.00 79.73 
66.66 40.00 40.32 40.00 68.35 68.00 100.00 75.00 72.87 
83.33 35.00 46.40 35.00 68.35 64.00 .00 50.00 43.26 
66.66 80.00 84.76 80.00 81.65 76.00 100.00 85.00 84.68 
58.33 80.00 79.85 80.00 73.35 72.00 100.00 80.00 81.20 
58.33 65.00 67.02 65.00 68.35 64.00 66.66 75.00 67.20 
75.00 40.00 42.27 40.00 50.00 52.00 66.66 35.00 50.92 
50.00 65.00 59.31 65.00 73.35 84.00 100.00 50.00 78.16 
58.33 40.00 35.45 40.00 50.00 64.00 33.33 65.00 50.90 
91.66 45.00 42.76 45.00 55.00 48.00 .00 55.00 72.74 
75.00 60.00 48.86 60.00 68.35 60.00 100.00 55.00 70.35 
70.00 69.41 70.00 81.65 80.00 100.00 65.00 81.44 
80.00 65.22 80.00 76.65 80.00 100.00 65.00 81.94 
5.00 26.77 5.00 45.00 32.00 .00 35.00 23.33 
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. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
1.00 1.00 .00 .00 .00 .00 .00 .00 .00 
3.00 1.00 .00 .00 3.00 .00 1.00 1.00 .00 
2.00 1.00 .00 .00 .00 .00 2.00 .00 .00 
2.00 1.00 .00 .00 .00 .00 .00 2.00 .00 
2.00 .00 .00 .00 .00 .00 .00 2.00 .00 
2.00 1.00 2.00 .00 .00 1.00 .00 .00 .00 
.00 .00 .00 .00 .00 .00 .00 .00 .00 
2.00 1.00 .00 .00 .00 2.00 .00 1.00 .00 
1.50 .00 .00 .00 .00 1.00 .00 1.00 .00 
1.50 .00 .00 .00 .00 1.00 .00 1.00 .00 
1.00 .00 .00 .00 1.00 .00 .00 .00 .00 
1.00 1.00 .00 .00 .00 .00 .00 .00 .00 
2.00 2.00 .00 .00 .00 .00 .00 .00 .00 
3.00 2.00 2.00 1.00 .00 2.00 1.00 .00 .00 
2.50 2.00 2.00 .00 .00 .00 .00 .00 .00 
3.50 1.00 1.00 .00 3.00 2.00 .00 .00 .00 
2.00 .00 2.00 .00 1.00 .00 .00 1.00 .00 
.00 2.00 .00 .00 .00 .00 2.00 .00 .00 
1.50 1.00 .00 .00 1.00 .00 1.00 1.00 .00 
. . . . . . . . .
.00 .00 .00 .00 .00 .00 .00 .00 .00 
1.00 .00 .00 .00 1.00 .00 .00 .00 .00 
3.50 .00 .00 .00 .00 .00 2.00 3.00 .00 
1.00 .00 .00 .00 1.00 .00 .00 .00 .00 
3.00 2.00 1.00 .00 2.00 2.00 .00 1.00 .00 
2.50 .00 .00 .00 1.00 2.00 .00 2.00 .00 
2.00 1.00 .00 .00 1.00 2.00 .00 .00 .00 
1.50 1.00 1.00 .00 .00 .00 .00 .00 .00 
.00 .00 .00 .00 .00 .00 .00 .00 .00 
2.50 1.00 1.00 1.00 .00 2.00 .00 2.00 .00 
.00 .00 .00 .00 .00 .00 .00 .00 .00 
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2.00 .00 .00 .00 .00 1.00 .00 .00 2.00 
1.00 .00 1.00 .00 .00 .00 .00 .00 .00 
1.50 .00 .00 .00 1.00 .00 .00 1.00 .00 
.00 .00 .00 .00 .00 .00 .00 .00 .00 
2.00 1.00 .00 .00 .00 .00 .00 2.00 .00 
.00 .00 .00 .00 .00 .00 .00 .00 .00 
.00 .00 .00 .00 .00 .00 .00 .00 .00 
.00 .00 .00 .00 .00 .00 .00 .00 .00 
1.00 .00 .00 .00 .00 .00 1.00 .00 .00 
3.00 .00 .00 .00 .00 .00 .00 3.00 .00 
1.00 .00 .00 .00 .00 .00 1.00 .00 .00 
1.00 1.00 .00 .00 .00 .00 .00 .00 .00 
3.50 .00 2.00 .00 1.00 .00 .00 3.00 .00 
.00 .00 .00 .00 .00 .00 .00 .00 .00 
1.00 1.00 .00 .00 .00 .00 .00 .00 .00 
1.50 1.00 .00 .00 .00 1.00 .00 .00 .00 
1.00 1.00 .00 .00 .00 .00 .00 .00 .00 
2.50 2.00 .00 1.00 1.00 1.00 .00 .00 2.00 
1.00 .00 .00 .00 .00 1.00 .00 .00 .00 
2.20 2.00 .00 .00 .00 .00 2.00 1.00 .00 
1.00 .00 .00 .00 1.00 .00 .00 .00 .00 
2.50 2.00 1.00 .00 1.00 2.00 .00 .00 .00 
2.00 .00 .00 .00 .00 1.00 2.00 1.00 .00 
1.50 1.00 .00 .00 1.00 .00 .00 .00 .00 
3.00 1.00 .00 .00 .00 .00 3.00 .00 .00 
.00 .00 .00 .00 .00 .00 .00 .00 .00 
3.50 1.00        
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. . . . . . . .
. . . . . . . .
. . . . . . . .
. . . . . . . .
. . . . . . . .
. . . . . . . .
. . . . . . . .
. . . 62.00 75.00 72.00 79.00 78.00 
92.00 77.00 89.00 3.00 . .00 70.00 93.00 
61.00 52.00 83.00 71.00 59.00 67.00 88.00 79.00 
91.00 66.00 89.00 71.00 85.00 70.00 92.00 71.00 
91.00 76.00 82.00 69.00 43.00 34.00 81.00 77.00 
59.00 82.00 89.00 67.00 56.00 49.00 83.00 63.00 
44.00 61.00 83.00 78.00 75.00 70.00 69.00 66.00 
76.00 80.00 71.00 50.00 53.00 71.00 90.00 76.00 
74.00 76.00 83.00 .00 41.00 53.00 74.00 81.00 
89.00 86.00 49.00 42.00 .00 64.00 86.00 82.00 
37.00 74.00 86.00 52.00 46.00 45.00 94.00 82.00 
97.00 68.00 94.00 72.00 85.00 54.00 67.00 83.00 
77.00 79.00 87.00 .00 . .00 78.00 77.00 
71.00 67.00 70.00 75.00 79.00 73.00 76.00 73.00 
77.00 64.00 85.00 76.00 47.00 66.00 84.00 83.00 
49.00 47.00 82.00 78.00 32.00 65.00 86.00 87.00 
87.00 64.00 70.00 .00 . . . . 
.00 44.00 76.00 64.00 20.00 72.00 91.00 73.00 
83.00 75.00 78.00 38.00 52.00 18.00 68.00 63.00 
77.00 76.00 88.00 . . . . . 
. . . 65.00 36.00 34.00 92.00 76.00 
86.00 71.00 82.00 87.00 70.00 70.00 84.00 77.00 
88.00 70.00 81.00 .00 39.00 76.00 66.00 87.00 
84.00 94.00 64.00 24.00 7.00 .00 93.00 76.00 
47.00 74.00 77.00 52.00 77.00 41.00 84.00 86.00 
51.00 .00 83.00 .00 40.00 27.00 72.00 74.00 
71.00 71.00 51.00 34.00 37.00 49.00 75.00 45.00 
89.00 56.00 71.00 .00 .00 56.00 86.00 83.00 
82.00 83.00 45.00 37.00 32.00 58.00 86.00 84.00 
87.00 92.00 81.00 57.00 .00 58.00 81.00 83.00 
83.00 89.00 92.00 62.00 60.00 60.00 87.00 88.00 
84.00 90.00 96.00 81.00 63.00 87.00 76.00 47.00 
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.00 27.00 75.00 11.00 47.00 61.00 80.00 78.00 
86.00 67.00 90.00 84.00 84.00 76.00 93.00 92.00 
90.00 92.00 90.00 59.00 76.00 78.00 82.00 85.00 
78.00 83.00 89.00 86.00 85.00 66.00 91.00 90.00 
90.00 90.00 84.00 44.00 .00 .00 79.00 83.00 
85.00 82.00 63.00 21.00 78.00 57.00 68.00 77.00 
78.00 72.00 93.00 40.00 31.00 42.00 49.00 71.00 
66.00 69.00 75.00 73.00 57.00 . 81.00 77.00 
90.00 78.00 90.00 . .00 38.00 75.00 76.00 
65.00 91.00 50.00 91.00 97.00 92.00 87.00 87.00 
96.00 84.00 92.00 42.00 36.00 36.00 81.00 83.00 
37.00 77.00 73.00 . . . . . 
. . . 86.00 93.00 83.00 87.00 92.00 
92.00 85.00 91.00 .00 .00 16.00 84.00 92.00 
92.00 83.00 85.00 72.00 57.00 73.00 81.00 84.00 
82.00 55.00 91.00 65.00 81.00 49.00 93.00 80.00 
85.00 81.00 83.00 70.00 87.00 77.00 71.00 67.00 
51.00 45.00 90.00 39.00 31.00 73.00 73.00 59.00 
61.00 78.00 86.00 64.00 .00 32.00 83.00 63.00 
30.00 53.00 89.00 85.00 86.00 71.00 90.00 81.00 
86.00 72.00 91.00 38.00 85.00 55.00 81.00 89.00 
66.00 85.00 82.00 63.00 52.00 64.00 78.00 91.00 
81.00 85.00 93.00 . . . . . 
. . . 72.00 83.00 42.00 79.00 64.00 
73.00 51.00 93.00 16.00 .00 62.00 95.00 60.00 
78.00 .00 .00 . . . . . 
59.00 21.00 50.00 81.00 83.00 
72.00 29.00 10.00 87.00 71.00 
20.00 17.00 44.00 83.00 83.00 
